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 Bona diagnosis, bona curratio 

  
ABSTRACT 
Hemophagocytic lymphohistocytosis (HLH) is a life-threatening hyperinflammatory condition characterized by fever, 
cytopenia, hepatosplenomegaly, and sometimes hemophagocytosis. HLH is typically divided into two distinct groups, 
primary HLH and secondary HLH. Familial HLH (FHL), of autosomal recessive inheritance, is divided into type 2, 3, 
4, and 5, caused by aberrations in PRF1, UNC13D, STX11, and STXBP2, respectively; all encoding proteins involved 
the perforin-mediated cytotoxic pathway. Consequently, patients with FHL display a defective NK cell cytotoxicity, 
one of the diagnostic criteria for HLH. The clinical presentation of the different forms of HLH can vary markedly, and 
the distinction between primary and secondary HLH is not always clear. 
In 1991, Henter et al. reported the first estimate of the annual incidence of FHL. Based on an increased 
awareness of HLH, with available diagnostic guidelines and increased clinical and biological understanding, we, in 
Paper I, hypothesized that the true incidence could be higher than previously estimated. However, somewhat 
surprisingly, the estimated annual incidence of primary HLH in Sweden was unchanged, 1.2 per million children less 
than 15 years of age, corresponding to 1.8 per 100 000 live born children. The annual incidence in patients aged less 
than 1 year was 11 per million children. The second part of Paper I aimed to provide a minimal incidence of primary 
HLH based on genetic findings and NK cell function consistent with primary HLH. Using these methods, twelve such 
patients referred to us were identified 2007-2011, giving a minimal incidence of 1.5 per million children aged less than 
15 years in Sweden, corresponding to 2.2 patients per 100 000 live born children. These laboratory diagnostic tools 
may facilitate the diagnosis of primary HLH. 
In many patients with primary HLH, especially in patients of Scandinavian origin, the underlying molecular 
defect has not been identified. Thus, one of the major aims with this thesis was to provide a genetic diagnosis for these 
patients. Patients with Griscelli syndrome type 2, another autosomal recessive immunodeficiency associated with 
development of HLH, display a partial albinism in addition to the immunological defect. In Paper II, one out of 21 
families diagnosed as having FHL, was identified with bi-allelic mutations in RAB27A, and thus instead affected by 
GS2. Three additional GS2 patients were also first diagnosed as having FHL and first later diagnosed with GS2, further 
stressing the importance of remembering GS2 among patients with HLH. The partial albinism in GS2 patients may 
easily be overlooked. In Paper III, Rab27a was shown to be required for NK cell cytotoxicity and degranulation 
induced by receptors both for natural cytotoxicity and antibody dependent cellular cytotoxicity, in contrast to what 
previously has been described. Furthermore, recruitment of Rab27a and Munc13-4 to perforin-containing granules was 
shown regulated by different receptor signals, with an inverse relationship between Rab27a and Munc13-4. 
In Paper IV, we describe the clinical presentation, the mutation spectrum, and NK cell function in patients with 
FHL type 5. Interestingly, a highly variable disease severity was observed among these patients, with an age at onset 
ranging from 2 months to 17 years. Furthermore, gastrointestinal symptoms, bleeding disorders, and 
hypogammaglobulinemia were present in about one third of the patients. Thus, we conclude that the clinical 
presentation of FHL type 5 can vary markedly, and that FHL5 should be considered also in patients with manifestations 
not typically associated with FHL. In Paper V, two non-coding aberrations in UNC13D were described to be causative 
of FHL type 3 in many patients of European origin, highlighting that aberrations outside the coding regions also can be 
a cause of disease. The first is a point mutation in intron 1 that selectively impairs UNC13D transcription in 
lymphocytes and the second is a 253-kb inversion straddling the UNC13D locus that affects the 3’end of the transcript. 
Both aberrations abolish the Munc13-4 expression. 
Taken together, this thesis provides genetic, cellular, and clinical findings of importance for the understanding 
of HLH. A genetic diagnosis, together with assessment of cytotoxic lymphocyte function, facilitates the diagnosis of 
patients with primary HLH and enables presymptomatic identification of affected individuals. Furthermore, a genetic 
diagnosis enables carrier testing and prenatal diagnosis in the affected families. Studies of cytotoxic lymphocyte 
function in these patients also provide fundamental insights in lymphocyte cytotoxic function and human immunology. 
A genetic diagnosis, together with an increased knowledge about the diverse clinical presentation, is highly valuable in 
the clinical management and for prompt initiation of adequate treatment in these life-threatening immunodeficiencies. 
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FOREWORD 
 
This thesis comprises studies of a group of inherited immunodeficiencies termed primary 
hemophagocytic lymphohistiocytosis (HLH). HLH is characterized by a disproportionate 
immune response and a severe systemic hyperinflammation. Without adequate treatment of 
HLH the prognosis is poor. My aim and hope when I started working with this thesis was to be 
able to improve the diagnostic work-up of severely sick children affected by HLH. It is 
rewarding that this aim now has been accomplished. An early and correct diagnosis is 
important for prompt initiation of adequate treatment and thus also for an improved outcome.  
 
The first part of the introduction aims to provide a general background about human 
immunology and human genetics for readers outside the field. This part is followed by a more 
specific introductory section about HLH and mechanisms of lymphocyte cytotoxicity, as well 
as a discussion about the findings and concluding remarks and future perspectives. The last 
section includes the five papers comprising the thesis. 
 
 
Stockholm, September 9, 2012 
 
Marie Meeths 
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1 INTRODUCTION 
 
1.1 HUMAN IMMUNOLOGY 
1.1.1 The immune system  
We are living in a hostile world with a continuous need for protection, and for survival 
our immune system is absolutely crucial. The different components of the immune 
system are defending us from invading pathogens and malignantly transformed or 
damaged cells. The immune system is complex and strictly regulated, in order to exert 
its function and still avoid self-damage. However, in spite of a functional immune 
system, we are still vulnerable to different infections. Infection-related mortality has 
over the years been high, and the increase in life expectancy, due to improved hygienic 
procedures, development of antimicrobial drugs and vaccination, is relatively recent.  
 
Primary immunodeficiencies (PIDs) have previously been considered as rare 
Mendelian disorders resulting in fatal infections during infancy. However, the last 
decade the knowledge of PIDs has increased considerably, and the underlying genetic 
defects have now been identified in many previously disparate syndromes associated 
with increased susceptibility to infection. The identification of the molecular defects 
has also resulted in identification of novel PIDs. There is currently an on-going debate 
about the definition of PIDs and today PIDs are also recognized as a cause of more 
subtle disease presentation [1, 2]. JL Casanova has introduced the concept of 
monogenic “holes” in immunity that cause susceptibility to specific infectious disease 
in otherwise healthy individuals [3], and the question is if  “inborn errors of immunity 
to infection” can be considered “the rule rather than the exception” [4].  
 
 
1.1.2 Hematopoietic stem cells 
The white blood cells are generated from a common progenitor, the pluripotent 
hematopoietic stem cell (HSC). This process, called hematopoiesis, is restricted to 
different parts of the body during different ages. In the embryo, the hematopoiesis first 
occurs in the yolk sac, later in the liver, and thereafter in the spleen. In the fourth or 
fifth fetal month, the hematopoiesis starts to shift to the bone marrow, and at birth the 
bone marrow is the main location for the hematopoiesis [5]. 
 
The HSCs are by definition self-renewing, undifferentiated cells that can give rise to all 
mature blood cells, of both lymphoid lineage (T cells, B cells, and Natural Killer cells 
(NK cells)) and myeloid lineage (erythrocytes, megakaryocytes/platelets, monocytes, 
macrophages, dendritic cells (DCs), granulocytes). HSCs are rare, counting for only 
one in thousand of the cells in the bone marrow [6]. Even though the HCSs are the 
most studied stem cell in humans, the complexity of these cells is not yet fully 
understood. It has been shown that HSCs constitute different subsets with fixed 
epigenetically determined differentiation and self-renewal programs; lymphoid biased 
HCSs, myeloid biased HCS, and balanced HCS. All types possess self-renewal 
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capacity and an ability to differentiate into all different types of mature cells, thus 
fulfilling the criteria for a pluripotent stem cell [7, 8].  
 
 
1.1.3 Basic overview of the innate and adaptive immunity  
The immune system is traditionally divided into two separate entities; the innate 
immunity and the adaptive immunity. The innate immune system conducts the initial 
immune response, with germ-line encoded receptors for recognition of targets. These 
receptors, evolved by natural selection, are limited in their diversity and recognize 
pathogen-associated molecular patterns (PAMPs), instead of specific disease-causing 
agents, pathogens, such as a virus, bacterium, or fungus. In contrast, T and B cells, 
mediators of the adaptive immunity, have an extreme diversity of receptors generated 
by somatic recombination. The term ‘antigen’ originally came from ‘antibody 
generator’ and means a substance that can induce an immune response by binding to 
the B cell receptor, an antibody, or to the T cell receptor. The cells with a receptor that 
specifically binds to an antigen can undergo clonal expansion, inducing a specific and 
efficient immune response. In contrast to the innate immune response, the adaptive 
response takes several days to develop on the first encounter of a pathogen. An 
important feature of the adaptive immune system is the immunological memory, 
favorable upon a second encounter of the specific pathogen. 
 
 
1.1.3.1 Innate immunity  
 
The innate immunity is characterized by fixed germ-line encoded receptors and effector 
molecules [9]. The physical barriers, including the skin and the mucosa, are the first 
line of defense against invading pathogens. In addition to the anatomical barrier, a 
diversity of antimicrobial agents, including peptides called defensins, are secreted from 
all epitheliums [10]. Damage to the barriers, enable the entry of pathogens into the 
body´s soft tissue.  
 
The complement system consists of serum proteins, produced in the liver [11]. They 
initiate a cascade of enzymatic reactions resulting in the cleavage of complement 
component 3 (C3) to C3a and C3b. C3b becomes covalently bound to the pathogen, 
and functions as a recognition-tag for phagocytic cells, a mechanism called 
opsonization.  C3b is also involved in the formation of the membrane-attack complex 
(MAC), which forms a pore in the plasma membrane and induces cell lysis in the 
pathogen. C3a is implicated in recruitment of phagocytes [11]. The complement system 
is divided into three different pathways; the alternative pathway, the lectin pathway, 
and the classical pathway. The classical pathway is implicated in both the innate and 
the adaptive immune response, which includes binding of antibodies to the pathogens’ 
surface. All three pathways converge at C3, finally ending up with the MAC complex, 
C5b-9 [11]. Of note, the structure of C9 in the MAC complex shows similarities to 
perforin, a pore-forming protein involved in lymphocyte cytotoxicity [12]. Defects in 
the complement system can lead to autoimmune manifestations or infections, such as 
the susceptibility to neisserial infections seen in patients with a deficiency in the MAC 
complex [13].  
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Monocytes are the circulating precursors of macrophages and dendritic cells (DCs). 
While migrating from the circulation into the tissues, they are differentiated into DCs 
and macrophages, professional phagocytic cells [14]. Macrophages have a variety of 
receptors recognizing signals not normally found in healthy tissues. Engagement of the 
receptors induces phagocytosis and destruction of the engulfed pathogen in a 
compartment called the phagolysosome [14]. The phagocytic capacity is enhanced by 
opsonization, coating of the pathogens by complement or antibodies. Toll-like 
receptors (TLRs) are a family of receptors that recognize different types of PAMPs [9, 
15]. Ten different TLR genes are so far identified in humans [9, 15]. Different family 
members of the TLRs respond to different microbial products, e.g., lipopolysaccharide 
(LPS), double stranded ribonucleic acid (RNA) (present in many viral infections), 
unmethylated CpG nucleotide motifs (abundant in bacterial and viral but not in human 
genomes), zymosan (derived from yeast cell walls) [5]. Together the TLRs recognize a 
large variety of microorganisms. TLR4 expressed by macrophages recognizes LPS, and 
are thus important in the defense against Gram-negative bacteria [9, 15]. Signaling 
through the TLR4 leads to recruitment of the adaptor proteins MyD88 or TIR-domain-
containing adapter-inducing interferon-" (TRIF) [9, 15]. Recruitment of MyD88 results 
in binding to IRAK-4 and activation of the transcription factor nuclear factor-!B (NF-
!B), important for both the innate and adaptive immune responses by upregulation of 
genes encoding pro-inflammatory cytokines, such as interleukin (IL)-1, IL-6, CXCL8 
(also known as IL-8), IL-12 and tumor necrosis factor-# (TNF-#) [16]. Signaling 
through the TRIF pathway results in activation of the transcription factor interferon 
response factor 3 (IRF3) and production of antiviral cytokines called type 1 interferons 
[16]. The TRIF pathway is also activated by the binding of microbial products, like 
double-stranded RNA components of some viral genomes, to TLR3 [5]. Defects in 
protein involved in TLR-mediated signaling result in a susceptibility to different 
specific pathogens [17]. Patients with defects in MyD88 and IRAK-4 suffer from severe 
and invasive bacterial infections [18, 19], whereas patients with herpes simplex 
encephalitis have been reported with inherited defects in the TLR3-immunity [20].  
 
Neutrophils are the most abundant white blood cells, circulating in the blood awaiting 
signals to be recruited to the site of infection. They are phagocytic cells that, in contrast 
to the macrophages, have a short lifetime of about two days. They are stored in the 
bone marrow for up to five days before being released into the peripheral blood. 
Neutrophils have receptors recognizing microbial products and opsonized pathogens. 
After engulfment and fusion of the phagosome with preformed neutrophil granules, 
different toxic substances and enzymes eliminate the pathogen. Nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase is essential in the elimination of the 
pathogen [5]. Individuals without functioning neutrophils are susceptible to fungal and 
bacterial infections [17]. Patients with chronic granulomatous disease have reduced 
neutrophil function due to defects in the NADPH-complex whereas severe congenital 
neutropenia (SCN) includes a heterogeneous group of disorders characterized by low 
neutrophil counts [17, 21, 22]. In addition to the susceptibility to bacterial and fungal 
infections, patients with SCN have an increased risk of leukemia-development. The 
cumulative incidence of myelodysplastic syndrome/leukemia in SCN patients has been 
reported to be 31 % [21].  
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NK cells were first described 1975 as large granular lymphocytes, encompassing 
cytotoxic capacity [23, 24]. NK cells comprise 15 % of the circulating lymphocytes 
[25]. They are defined as cells of the innate immunity, with a key role in the defense 
against intracellular viral and bacterial pathogens, as well as neoplastic cells. In 
addition to their cytotoxic capability of killing their target cells, they are important 
cytokine secreting cells [26]. They are in the early stage of an infection the main 
producers of IFN-$, a type II interferon [26]. IFN-$ activates the macrophages to 
secrete cytokines, initiating the adaptive immune response. Their ability to kill their 
targets is enhanced by activation by interferons, such as IFN-# and IFN-" induced by 
viral infections [26]. Type I interferons also induce proliferation of the NK cells. IL-12 
is a potent activator of IFN-$ production in NK cells [26]. NK cells also play an 
important role in the control of expansion of autologous immune cells [27]. Of interest, 
several reports of NK cell-mediated adaptive immunity have been published the last 
decade, providing evidence for NK cell memory [28]. Patients with NK cell-deficiency 
are susceptible to viral infections, especially to the herpesvirus and papillomavirus 
families [29].   
 
 
1.1.3.2 Adaptive immunity  
 
The adaptive immunity is characterized by a highly specific, adaptable, and efficient 
immune response, which, in contrast to the innate immune system, takes several days to 
be fully functioning upon the first encounter of a specific pathogen. The adaptive 
immunity can be divided into the cell-mediated and the humoral immunity, conducted 
by T cells and B cells, respectively. The receptors for antigen recognition are all of the 
same molecular type and are highly specific in contrast to the receptors in the innate 
immunity. The receptors are encoded by genes allowing rearrangement leading to 
production of a huge variety of receptors [30-32]. 
 
Immature B cells are produced in the bone marrow. B cells are characterized by 
expression of the B cell receptor, an immunoglobulin, specifically recognizing the 
antigens. The immunoglobulin consists of two heavy chains and two light chains. They 
have a variable region binding the antigen, and a constant region that is very similar 
between the different immunoglobulins. For the soluble immunoglobulins the constant 
region binds to Fc receptors on phagocytes and cytotoxic cells, inducing antibody-
mediated phagocytosis and antibody-dependent cellular cytotoxicity (ADCC), 
respectively. The T cell receptors (TCRs) are always membrane-bound, and consist of 
an #-chain (TCR#) and a "-chain (TCR"), or alternatively, in a minority of cases, a $-
chain and a %-chain. Similarly to the B cell receptor, the TCRs have a variable region 
for specific binding of the antigen, and a constant region.  
 
The variable regions of immunoglobulins and TCRs are encoded by gene segments 
called V, D, and J. The heavy chain gene in the immunoglobulin and the "-chain gene 
in the TCR have arrays of V, D and J segments, whereas the light chain and the #-chain 
only include V and J segments. An enzyme-catalyzed process, where different 
combinations of the segments are brought together, called rearrangement, is required to 
acquire a functional gene. This process takes place in the somatic cells and is called 
somatic recombination [5]. Two of the enzymes involved in the rearrangement are 
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recombination activating gene (RAG)-1 and RAG-2, expressed only in T cells and B 
cells [33]. These enzymes are essential for the adaptive immunity, and the RAG genes 
and the adaptive immunity are thought to have arisen in ancestors of jawed vertebrates 
approximately 500 million years ago [34]. 
 
The somatic recombination results in a diversity of specific receptors and production of 
millions of different variants of circulating lymphocytes. Upon infection by a pathogen, 
only a small subset of the lymphocytes will have receptors recognizing the specific 
antigen. The adaptive immune response is initiated in specialized lymphoid tissues such 
as lymph nodes, spleen, and Peyer’s patches in the intestines. This promotes the 
meeting of the small numbers of lymphocyte with the specific antigens, but requires 
presentation of the pathogen by different antigen presentation cells (APCs) such as the 
DCs. Upon binding to a naïve T-cell with a receptor specific for the antigen (clonal 
selection), the T cell starts to proliferate to produce a clone with the specific receptor 
(clonal expansion). Upon proliferation, they differentiate into different effector 
lymphocytes with specific capacities [5].  
 
The antigen recognized by the TCRs are short peptides presented by the APCs. The 
peptide is generated by degradation of the pathogen proteins in the APCs and presented 
bound to a major histocompatibility complex (MHC) molecule. There are two types of 
MHC molecules, MHC class I and MHC class II. MHC class II molecules present 
antigens from extracellular pathogens, and is expressed by APCs. MHC class I is 
expressed by almost all cells and presents antigens from intracellular pathogens.  
 
Cytotoxic T cells (CTLs) are activated by engagement of the TCR. In addition, binding 
of the co-receptor CD8 to a conserved site on the MHC I molecule is necessary for 
target cell killing of infected cells [5]. The helper T cells instead express the co-receptor 
CD4, which binds to a conserved site of the MHC class II molecule. T helper cells 
enhance the phagocytosis of extracellular pathogens by macrophages and neutrophils 
either by direct contact with macrophages or by secretion of activating cytokines. 
Similarly, binding of or cytokine secretion by T helper cells is essential for 
differentiation and production of antibodies by the B cells. 
 
When the activated B cells proliferate, somatic hypermutation of the immunoglobulin 
takes place, producing immunoglobulins that bind the pathogen more tightly than the 
original B cell receptors [35]. B cells with strong binding are chosen for becoming 
plasma cells, effector cells specialized in antibody production. Class switching 
recombination (CSR) is another mechanism for a more efficient response that changes 
the constant region of the immunoglobulin but does not involve the variable antigen-
binding site [36]. Five different isotypes of immunoglobulins are produced, IgA, IgD, 
IgE, IgG, and IgM. IgM and IgD are cell surface antigen receptors on B cells. The main 
secreted antibodies are IgM, IgA and IgG. CRS enables production of the preferable 
isotype depending on requirements of the immune response for a specific pathogen 
[37]. Defects in the production of antibodies are associated with an increased 
susceptibility to bacterial infections, particularly affecting the upper respiratory tract 
[17]. X-linked agammaglobulinemia is the most common form of early onset 
agammaglobulinemia. Common variable immunodeficiency disorders, with reduced 
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levels of one or more subclasses of antibodies, is the most common clinically 
significant PID presenting mainly in adult age [17].  
 
Immunological tolerance towards self is needed to avoid self-damage, and includes 
mechanisms to avoid T cells with receptors recognizing self-antigens. Positive selection 
takes place in the thymus, and identifies thymocytes (immature T cells) carrying TCRs 
that efficiently bind to MHC molecules. Those T cells not binding MHC molecules 
undergo apoptosis. Negative selection is the mechanism where the surviving T cells 
that bind too strongly to self-MHC undergo apoptosis. A similar mechanism of 
negative selection of B cells takes place in the bone marrow. However, since the B cells 
need the T helper cells for the proliferation the necessity of self-tolerance is not as 
critical. Another mechanism for self-tolerance is regulatory T cells, which suppress 
responses of self-reactive T cells [38]. 
 
The clonal expansion of pathogen-specific B and T cells also lead to production of 
memory cells allowing for an immunological memory that can last for life. One of the 
advantages with the adaptive immune system is that a second encounter of the same 
pathogen results in a much faster and more efficient immune response. 
 
Severe combined immunodeficiency (SCID) comprises disorders with genetically 
determined defects in T cell differentiation together with variable defects in the 
differentiation of other linages [39]. SCID is classified based on the immunological 
phenotype with absence of T cells but not B cells or absence of both T and B cells. 
Both groups include forms with or without NK cells [17]. SCID can be of both X-
linked and autosomal recessive inheritance. The patients present early in life with life-
threatening infections, chronic diarrhea, and failure to thrive [17]. Thymic defects, 
including DiGeorge syndrome, may also result in T cell deficiency [17]. Defects in the 
cell-mediated cytotoxicity include both the innate and the adaptive immune system, and 
will be described in more detail later. 
 
 
1.2 HUMAN GENETICS  
1.2.1 Basic overview 
In 1865, Gregor Mendel published the seminal paper ‘Experiments on Plant 
Hybridization’ upon which the discipline of classical genetics was founded [40]. In this 
paper he described inherited characteristics in plants, with one trait being dominant to 
the recessive alternative, today called the Mendelian inheritance. The paper was not 
highly recognized initially, but was re-discovered in the early 1900s.  
 
In 1882, another German scientist, Walther Flemming, identified thread-like structures 
in the nucleus of the cell, later named chromosomes [41]. Humans have 23 pairs of 
chromosomes in the cell nucleus, of which 22 pairs are autosomes and one pair is sex 
chromosomes. In each pair, one chromosome is inherited from each parent. Each 
chromosome consists of a single deoxyribonucleic acid (DNA) molecule. In 1944, 
Oswald Avery, Colin McLeod and Maclyn McCarty reported DNA to constitute the 
hereditary material in bacteria [42]. The DNA molecule consists of polymers of the 
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nucleotides adenine, cytosine, guanine, and thymine, forming two strands running in 
opposite directions. This double-helix structure of DNA was first described by Watson 
and Crick in 1953 [43]. To fit in the cell nucleus, the DNA double-helix is packed 
together with histones and other proteins forming a structure called chromatin. The 
human genome consists of about 20 000 to 25 000 genes [44], which are the functional 
units of DNA encoding a protein or RNA. The composition of RNA is similar to DNA, 
except that RNA contains ribose in contrast to DNA that contains deoxyribose. 
Furthermore, thymine is replaced by uracil in RNA. The DNA is transcribed into RNA, 
which after post-transcriptional modifications is translated into a chain of amino acids, 
forming proteins. The post-transcriptional modifications include 5' capping, 3' 
polyadenylation, and RNA splicing. Splicing is the mechanism in which non-coding 
sequences, introns, in the gene are removed. The genetic code describes how a set of 
three nucleotides, a codon, is translated into a specific amino acid. Upon cell division 
the genome is duplicated by replication of the DNA molecules, providing 46 
chromosomes to each daughter cell.  
 
Mutations are variants in the DNA caused by mistakes in the replication or by 
environmental factors. If a mutation arises during meiosis, it can be inherited by the 
offspring. This individual will carry the mutation in all cells, called a constitutional 
mutation. The children of a carrier of a constitutional mutation can, in turn, inherit the 
mutation. In opposite, a somatic mutation arises only in the somatic cells, and will not 
be passed on.  
 
A mutation causative of disease is called a pathogenic mutation. A mutation can 
involve large segments of DNA, e.g., large duplications, deletions, or inversions, or 
smaller fragments e.g. small deletions or insertions, or single base pair exchanges. The 
small deletions and insertions can result in loss or gain of amino acids and/or cause 
shifts in the reading frame during translation. A mutation of a single base pair, a point 
mutation, introducing a stop codon in the reading frame is called a nonsense mutation. 
A missense mutation is a point mutation resulting in a change of a codon to one coding 
for a different amino acid, whereas a silent mutation does not result in a change of the 
amino acid. Certain genetic variants are more common in the population, called 
polymorphisms. A single nucleotide polymorphism (SNP) is an exchange of a single 
nucleotide, existing at different allele frequencies in different populations.  
 
 
1.2.2 Mendelian diseases and inheritance patterns 
A Mendelian trait, or disease, is controlled by a single locus, and follows the rules of 
Mendelian inheritance in contrast to multifactorial diseases. For each trait, one gene 
variant is inherited from each parent. The alternative gene variants are called alleles. If 
the alleles are identical they are called homozygous, and if they are not identical they 
are called heterozygous.  
 
Mendelian diseases can be autosomal or X-linked, depending on the location of the 
gene responsible for the disease. A disease is dominant if heterozygous carriers display 
the phenotype, and recessive if only homozygous or compound heterozygous (different 
mutation on the two alleles of a gene) carriers are affected. Furthermore, mutations can 
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have different penetrance (the proportion of mutation carriers of the genotype that 
develop the phenotype), and expressivity (the degree to which the genotype is 
phenotypically expressed). The “Online Mendelian Inheritance in Man” (OMIM), is a 
database of human genes and genetic disorders.  
 
 
1.2.3 Sequencing of the human genome 
The human genome-project was initiated 1984 with the primary role to determine the 
sequence of the human genome. In 2001 two separate drafts of the human genome were 
published, by the International Human Genome Sequencing Consortium (IHGSC) and 
by the privately funded Celera Genomics, respectively [45, 46]. In 2004 the IHGSC 
reported the results of the finished project [44], and in 2007 the first sequence of an 
individual human genome was published [47]. The last years there has been a shift 
from conventional Sanger sequencing to newer methods referred to as next-generation 
sequencing (NGS) [48]. NGS platforms are now widely available and the cost of DNA 
sequencing is constantly decreasing, allowing for production of an enormous amount of 
sequencing data. The 1000 genomes project is the first project to sequence a large 
number of people and has the goal to identify most of the variants with a frequency 
over 1 % in the populations studied. The results of the pilot-phase of the study were 
published in 2010 [49]. Sequencing of only the coding regions of the genome, 
constituting less than 2 %, is termed whole-exome sequencing. This approach reduces 
the costs and has been proven a useful tool in discovering Mendelian disease genes 
[50].   
 
 
1.3 HEMOPHAGOCYTIC LYMPHOHISTOCYTOSIS  
1.3.1 History, classification, and diagnostics  
James W. Farquhar and Albert E. Claireaux in 1952 described two children with a 
rapidly fatal disease, none of them diagnosed before death. Farquahar and Claireux 
diagnosed these children with what they named familial hemophagocytic reticulosis 
[51]. The term familial hemophagocytic reticulosis was later changed to familial 
hemophagocytic lymphohistiocytosis (FHL). One year earlier, in 1951, Reese and Levy 
had reported two sisters diagnosed with Letter-Siwe disease, which both died in infancy 
with fever, cytopenia, hepatosplenomegaly, hemophagocytosis. Retrospectively this 
probably represent the first siblings with FHL reported in the medical literature [52].     
 
The clinical presentation of hemophagocytic lymphohistiocytosis (HLH) is 
characterized by prolonged fever, hepatosplenomegaly, and cytopenia [53-55]. Other 
common findings include high fasting triglycerides, low fibrinogen, high ferritin, 
hepatitis/acute liver failure, elevated sCD25, and hemophagocytosis [53-55]. 
Furthermore, neurological involvement with neurological symptoms and/or 
pathological cerebrospinal fluid (CSF) is common, and is, importantly, sometimes the 
first symptom [56-59].  Of note, the presentation of HLH can vary markedly between 
different patients.  
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HLH is typically divided into two different entities, primary HLH and secondary HLH. 
The primary form is caused by inherited genetic aberrations, whereas there is no clear 
inheritance pattern of secondary HLH. Secondary HLH can be triggered by an 
underlying infection, a malignancy, or a rheumatological disorder. These different 
types are termed infection-associated HLH, malignancy-associated HLH, and rheuma-
associated HLH, respectively. The latter is also often called macrophage activation 
syndrome [60]. The distinction between primary and secondary HLH is not always 
clear.  
 
As the clinical presentation of HLH is diverse, there is often a delay in making the 
diagnosis. To guide the treating clinicians, the first diagnostic guidelines for HLH were 
published in 1991 by Henter et al. [61]. These criteria were also used in the first 
international treatment protocol, HLH-94 (Table 1) [62]. The currently used criteria 
were published together with the updated treatment protocol, HLH-2004 (Table 1) [63].  
 
Table 1. Diagnostic criteria for HLH according to HLH-94 and HLH-2004 [62, 63]. 
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Splenomegaly 
Bicytopenia 
     Hemoglobin (Hb) <90 g/L (infants <4 weeks: Hb <100 g/L)  
     Platelets <100!109/L  
     Neutrophils <1.0 !109/L 
Elevated triglycerides and/or decreased fibrinogen 
     Fasting triglycerides "3.0 mmol/L (i.e., <265 mg/dl) 
     Fibrinogen #1.5 g/L 
Hemophagocytosis in bone marrow, spleen or lymphnodes 
    No evidence of malignancy 
Ferritin >500 mg/L   
sCD25 (i.e., $-chain of soluble IL-2 receptor) >2,400 U/ml   
Defective NK cell function (according to local laboratory)   
Criteria for the diagnosis of HLH according to HLH-94 and HLH-2004, respectively. 
In addition, a positive familial history, and consanguinity are suggestive of HLH 
according to HLH-94 [62, 63]. 
 
 
1.3.2 Genetics in FHL 
In 1999, the first two genetic loci associated with FHL were reported back-to-back [64, 
65]. FHL1 (9q21.3-22, Table 2) was identified by homozygosity mapping of four 
inbred families of Pakistani origin [65]. The disease-causing gene has so far not been 
identified in this locus, whereas Stepp et al. later the same year described PRF1 as the 
causative gene of FHL2 (Table 2) [66]. PRF1 encodes perforin, involved in cytotoxic 
lymphocyte function. In 2003, the FHL3 locus was mapped to 17q25 in 10 patients 
from 7 unrelated families and UNC13D (Table 2), encoding Munc13-4, was identified 
as the causative gene by Feldmann et al. [67]. Genome-wide homozygosity mapping in 
a large consanguineous family of Kurdish origin revealed linkage to 6q24, defining the 
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FHL4 locus, and homozygous mutations were identified in STX11 (Table 2) in this and 
other families in 2005 [68]. Lastly, two different research groups in 2009 assigned 
FHL5 to 19p13, and the fourth gene, STXBP2 (Table 2), causative of FHL was 
identified [69, 70]. STX11 and STXBP2, encode syntaxin 11 and Munc18-2, 
respectively. The function of these four proteins will be described in the section entitled 
‘Mechanisms of lymphocyte cytotoxicity’.  
 
 
1.3.3 Primary hemophagocytic syndromes 
In addition to FHL with an autosomal recessive inheritance, primary hemophagocytic 
syndromes also include other syndromes.  
 
Griscelli syndrome type 2 (GS2) and Chediak-Higashi syndrome (CHS) are both 
autosomal recessive primary immunodeficiency syndromes associated with 
development of HLH in addition to a partial albinism. GS2 and CHS are caused by 
mutations in RAB27A and LYST, respectively (Table 2) [71, 72]. Patients with CHS 
have leukocyte cytoplasmatic giant-granules, not present in GS2 patients [71, 73]. In 
addition, patients with CHS have been described with a bleeding tendency and 
neurological impairments. The neurological symptoms in CHS may progress also after 
a hematopoietic stem cell transplantation (HSCT) [74].  
 
HLH has also been described in a patient with Hermansky-Pudlak syndrome type 2 
(HPS2), another autosomal recessive primary immunodeficiency with partial albinism, 
caused by defects in AP3B1 (Table 2) [75, 76]. Of note, the patient described also 
carried a heterozygous mutation in RAB27A, and was first suspected to have GS2. 
Other symptoms associated with HPS2 are bleedings, recurrent infections, and 
neutropenia [77, 78].   
 
X-linked lymphoproliferative syndrome (XLP) is a primary immunodeficiency 
characterized by vulnerability to Epstein-Barr virus (EBV), frequently complicated by 
development of HLH [79].  XLP is divided into two different subtypes, XLP1 and 
XLP2, caused by mutations in SH2D1A and XIAP, respectively (Table 2) [80, 81]. In 
both groups of patients, HLH episodes are often triggered by an EBV-infection [82]. 
Hypogammaglobulinemia has been documented in XLP1 and XLP2 patients, however 
to a greater extent in the XLP1 patients [82]. About one third of XLP1 patients develop 
lymphoma in contrast to none of the reported XLP2 patients [82]. In patients with 
XLP2, splenomegaly without fulminant HLH and colitis have both been reported [82]. 
SAP, encoded by SH2D1A, is a regulator of NKT cell development resulting in a lack 
of NKT cells in patients with XLP1, which is not observed in XLP2 patients [83, 84]. 
Furthermore, an impaired development of memory B cells is seen in XLP1 patients and 
the patients fail to produce an isotype class switched immune response after 
vaccinations [85]. 
 
Mutations were recently identified in IL-2–inducible T cell kinase (ITK, Table 2) in two 
sisters with a clinical picture resembling XLP, including EBV positive B cell 
proliferation following EBV-infection [86]. In contrast to the genes causative of XLP, 
ITK is an autosomal gene. Thus ITK-deficiency can affect both males and females.  
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Table 2. Genes associated with primary HLH. 
 
 Causative gene Locus Year of identification of 
the causative gene/locus 
FHL    
FHL1 Unknown 9q21.3-22 1999 
FHL2 PRF1 10q22.1 1999 
FHL3 UNC13D 17q25.1 2003 
FHL4 STX11 6q24.2 2005 
FHL5 STXBP2 19p13.2 2009 
Other immunodeficiencies often 
associated with HLH-development 
   
GS2 RAB27A 15q21.3 2000 
CHS LYST 1q42.3 1997 
HPS2 AP3B1 5q14.1 1999 
XLP1 SH2D1A Xq25 1998 
XLP2 XIAP Xq25 2006 
ITK-deficiency ITK 5q33.3 2009 
 
 
1.3.4 Secondary hemophagocytic lymphohistiocytosis 
Secondary HLH can complicate an underlying disease in both children and adults. Even 
though secondary HLH is not a Mendelian disorder, underlying genetic defects 
predisposing for HLH might be revealed in the future. 
 
Among infection-associated HLH, EBV is the most commonly reported triggering 
pathogen, especially in Asia [87]. Other viruses identified as triggers of HLH are 
human herpes virus 6, cytomegalovirus, adenovirus, parvovirus, and varizella-zoster 
virus [87]. In addition, bacteria, fungi, and protozoae can also trigger HLH [87]. A 
noteworthy trigger of HLH is Leishmaniasis, reported in many cases [88]. However, a 
triggering pathogen does not rule out primary HLH [89].  
 
Malignancy-associated HLH has most commonly been reported in patients with 
lymphomas and leukemias of T-cell or NK-cell lineages, but can also be associated 
with anaplastic large cell lymphomas, B lineage lymphoblastic leukemias, myeloid 
leukemias, mediastinal germ cell tumors, and other solid tumors [90]. Of importance, 
some patients develop HLH before the underlying malignancy is detected [91].    
 
Macrophage activation syndrome (MAS) is a severe, sometimes life-threatening 
complication to rheumatological diseases, especially systemic-onset juvenile idiopathic 
arthritis, adult-onset Still’s disease, and systemic lupus erythematosus [55]. MAS 
patients may present with all characteristics of HLH, and MAS has been suggested to 
instead be termed secondary HLH [60].  
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1.3.5 Pathogenesis and pathophysiology  
HLH is a hyperinflammatory condition characterized by a disproportionate immune 
response. Identification of the underlying genetic defects in patients with HLH and the 
increased knowledge about the function of the encoded proteins, have led to a better 
understanding of the pathogenesis and pathophysiology of HLH. All the known genes 
causative of FHL encodes proteins involved in lymphocyte cytotoxicity. Of note, 
defective lymphocyte cytotoxicity was described in FHL patients already in 1978 [92], 
and was suggested a diagnostic criterion for HLH in 1984 [93]. It was included in the 
diagnostic criteria in the HLH-2004 protocol [21].  
 
FHL is characterized by an excessive proliferation and activation of CTLs upon 
triggering of the immune system. The CTLs secrete pro-inflammatory cytokines, which 
activates macrophages. Tissues are infiltrated by these polyclonal CTLs and 
macrophages, and the activated macrophages phagocytose blood cells, called 
hemophagocytosis. In FHL patients, the feedback mechanism with down regulation of 
the immune response via perforin-dependent cytotoxicity is defective, allowing the 
hyper-inflammatory state to continue. Patients with secondary HLH do not have 
permanently defective lymphocyte cytotoxicity. However, they can have a transient 
defect, such as due to low numbers of cytotoxic cells.  
 
The pronounced hypercytokinemia in patients with HLH was first described in 1991 
[94]. The elevated levels of IFN-$, TNF-#, and IL-6 suggested an important role of pro-
inflammatory cytokines in the pathophysiology of HLH. Other cytokines e.g., IL-10, 
and macrophage colony-stimulating factor, have later also been described elevated in 
HLH patients [95, 96]. In perforin-deficient mice, an animal model of HLH, IFN-$ was 
shown to be essential for development of the HLH features upon infection with 
lymphocyte choriomeningitic virus (LCMV) [97]. The IFN-$ production appeared to be 
driven by increased antigen presentation to the CD8+ T cells [97]. It was later revealed 
that blocking of IFN-$ had a therapeutic effect of HLH in LCMV infected perforin-
deficient mice, as well as in Rab27a-deficient mice, the animal model of GS2 [98].  
 
 
1.3.6 Clinical and laboratory features  
The tissue infiltration of lymphocytes and macrophages together with the 
hypercytokinemia explain many of the clinical and laboratory features of HLH (Figure 
1). Fever can be induced by the increased levels of the pyrogenic cytokines IL-1, IL-6, 
and TNF-# [29]. The cytopenia is secondary to inhibitory effects of cytokines on the 
hematopoiesis, in addition to the hemophagocytosis of activated macrophages [97, 99, 
100]. The activated macrophages secrete ferritin and plasminogen activator, resulting in 
the elevated levels of ferritin and decreased levels of fibrinogen seen in patients with 
HLH [55]. The hypertriglyceridemia observed in many patients can be attributable the 
suppression of lipoprotein lipase activity by inflammatory cytokines such as TNF-# 
[101, 102]. Soluble CD25 (sCD25, the #-chain of the interleukin 2-receptor), typically 
elevated in HLH patients, is upregulated on activated T cells [103]. The 
hepatosplenomegaly is a result of tissue infiltration of activated T cells and 
macrophages. Neuropathological studies of patients with CNS involvement have 
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revealed lymphocyte and monocyte infiltration, which may secrete damaging cytokines 
and neurotoxic factors [56, 59].  
 
Figure 1. Schematic view of the pathophysiology of primary HLH.
 
 
1.3.7 Therapy and outcome 
1.3.7.1 Chemo-immunotherapy 
 
HLH can be rapidly fatal, and without treatment the median survival in FHL is between 
one and two months after diagnosis [104, 105]. The estimated 5-year survival was 17 % 
in a report of 122 patients published in 1996 [106]. These patients were not treated 
according to any common consensus protocol for HLH. Successful treatment including 
podophyllotoxin derivatives (teniposide and etoposide) and corticosteroids was first 
reported in the 1980s [107-109]. Later on, cyclosporine A was reported to be useful in 
the continuation treatment of primary HLH [110].   
 
The first prospective international treatment protocol, HLH-94, was developed by the 
Histiocyte Society and opened in 1994. The inclusion criteria in the study are described 
on page 9 (Table 1) [62]. The induction therapy in HLH-94 was based on etoposide, 
dexamethasone, and, in selected patients, intrathecal methotrexate [62]. The 
continuation therapy included etoposide, dexamethasone pulses, and cyclosporine A, 
and started after the 8-week induction [62]. A HSCT was recommended for patients 
with a familial disease, preferable with an HLA-identical donor if available [62]. HLH-
94 was closed in the end of 2003, and the long-term results of the study were published 
last year [111]. In total 249 patients were eligible for inclusion. After the initial 
treatment of 2 months, 214 patients (86 %) were alive, and 122 of 207 (59 %) of these 
patients were reported with non-active disease [111]. The 5-year probability-of-survival 
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was reported to be 54±6 % [111]. Overall, 124 (50%) patient underwent HSCT after a 
median time of 6.1 months [111]. 
 
The HLH-2004 protocol was based on the experience from the HLH-94 protocol, 
aiming to further improve the outcome. In addition to etoposide and dexamethasone, 
cyclosporine A was included in the induction therapy [63]. Patients with a familial 
history, known genetic diagnosis, or with severe, persistent or reactivated HLH were 
recommended continuation therapy, and for these patients HSCT was recommended as 
early as possible [63]. Patients without a known familial history that responded well to 
treatment with complete resolution were recommended to be put off treatment and 
closely followed in regards to HLH parameters [63]. The HLH-2004 study was closed 
end of 2011. The HLH-2004 study was closed end of 2011 and the results of the study 
are yet not published.  
 
The relationship between clinical findings and early pre-transplant deaths were studied 
in 232 patients treated with either HLH-94 or HLH-2004 [112]. Hyperbilirubinemia, 
hyperferritinemia, and cerebrospinal fluid pleocytosis at diagnosis were identified as 
risk factors for an adverse outcome, and trombocytopenia and hyperferritiemia were 
risk factors 2 weeks into therapy [112]. Moreover, the treatment of GS2, CHS, and 
XLP with HLH-94 and HLH-2004 has been evaluated in a small cohort [113]. The 
results suggest that HLH-directed therapy is effective in inducing remission of HLH in 
these syndromes [113].  
 
Results of an alternative treatment regimen of FHL, including antithymocyte globulins 
(ATG), used in a single-center study of 38 patients were reported 2007 [114]. A 
combination of ATG, corticosteroids, cyclosporine A, and intrathecal methotrexate 
were used. The therapy led to rapid and complete response in 73 % of the cases, and 
partial response in 29 % [114]. One patient did not respond to treatment at all and ten 
patients relapsed, whereof nine subsequently died [114]. In total, 79 % patients 
underwent HSCT and the overall survival was 55 % [114]. The efficacy of the ATG-
based regimen and HLH-94 is difficult to compare since no randomized has been 
performed. However, the overall survival is essentially similar, 55 % and 54 %, 
respectively. Notably, while the ATG study was performed in one single experienced 
center, HLH-94 was a multinational study [62, 114]. A trial using a “hybrid” 
immunotherapy combining ATG, corticosteroids, and etoposide is currently open.  
 
In addition to the above mentioned treatment regimens, alemtuzumab has been 
suggested a therapeutic role in the treatment of refractory HLH and rituximab has been 
used in EBV-associated HLH and XLP [115-117]. Furthermore, IFN-$ blocking 
antibodies have been suggested a putative therapeutic role in HLH, based on the 
function of IFN-$ in the pathophysiology described above [98, 118].  
 
For reliable comparison between the different treatment regimens, randomized studies 
are needed. Since the number of HLH patients is limited, international collaboration is 
vital for recruitment of a sufficient number of patients. 
 
 
  15 
1.3.7.2 Hematopoietic stem cell transplantation  
 
The first allogeneic HSCT for a HLH patient was reported with a favorable outcome in 
1986 [119]. Further strengthening the role of HSCT in the treatment of FHL, an 
increased estimated 5-year survival for patients that had undergone a HSCT compared 
to those without (66 % compared to 10 %) was seen in 122 patients [106]. 
 
In the HLH-94 protocol the conditioning regimen and graft-vs-host disease prophylaxis 
were determined by the different transplantation units. The outcome of HSCT in 
patients treated with the HLH-94 protocol has been evaluated by Horne et al. [120]. 
Altogether 86 patients were included in that study, with a median age of 13 months at 
HSCT. The 3-year over-all survival post-HSCT was 64 % ± 10 % [120]. Sub-divided 
into different donor groups the 3-year survival was 71% ± 18 % for matched related 
donors, 70 % ± 16 % for matched unrelated donors, 50 % ± 24 % for familial haplo-
identical donors, and 54 % ± 27% for mismatched related donors [120]. Based on this, 
the use of alternative donors at experienced centers was suggested when matched 
donors are unavailable [120]. Thirty-one patients were deceased at the point of 
analyses, whereof 26 were reported with transplant-related mortality, and two with 
relapse of HLH. Of note, patients with a better response to the pre-transplant induction 
therapy had a better outcome. 
 
In the evaluation of the ATG-based regimen the post-HSCT survival was 74 % [114]. 
Among patients treated with the ATG-based regimen as the first-line therapy the 
outcome was better, 84 % (n = 19) compared to 50 % (n = 8) of patients treated with 
the ATG-therapy as second-line treatment [114]. Of note, all patients in this study were 
treated at the same, highly experienced center, as compared to those in the multi-center 
HLH-94 study. The median time between onset of therapy and HSCT was 6 weeks 
(range 4-32 weeks) [114]. 
 
Two different studies, with twelve and 26 patients respectively, indicate a favorable 
outcome with reduced-intensity care conditioning (RIC) regimen compared to 
myeloablative conditioning [121, 122]. In one study, the estimated 3-year survival was 
92 % ± 11 % for RIC patients and 43 % ± 26 % for myeloablative conditioning patients 
[121, 122]. The other study reported 84 % of the RIC patients to be alive and well after 
HSCT with a median follow up of 36 months [121, 122]. Mixed donor-recipient 
chimerism was more frequent in RIC patients than myeloablative conditioning patients, 
65 % compared to 18 %. The only patient relapsing in that report did so after the whole 
blood donor chimerism fell to <10 % [122]. Another study of HSCT in HLH, describe 
sustained remission for up to 20 years in all patients with a donor chimerism > 20 % 
[123].  
 
With regard to disease activity at HSCT, Horne et al. reported that many patients 
survived HSCT despite active HLH at the time of transplant, and that HSCT therefore 
not automatically should be precluded in HLH patients with active disease [120]. These 
findings were later supported by another study, which reported acceptable survival in 
all patients groups except those with both active disease and haploidentical donors 
[123]. Nevertheless, it is still strongly suggested, if possible, to perform HSCT in a 
state of remission.  
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1.4 MECHANISMS OF LYMPHOCYTE CYTOTOXICITY 
CTLs and NK cells are cytotoxic lymphocytes important in the immune response to 
intracellular pathogens, and malignantly transformed cells, and for the immune 
homeostasis. Cytotoxic lymphocytes kill their target cells via the perforin-mediated 
pathway, involving directed secretion of secretory lysosomes, as well as, to some 
extent, death receptor signaling. The perforin-mediated pathway for lymphocyte 
cytotoxicity is schematically illustrated on page 21 (Figure 2).  
 
1.4.1 Secretory lysosomes  
A defining factor for mature cytotoxic lymphocytes are the secretory lysosomes. These 
are specialized lysosomal organelles, containing the secretory proteins perforin and 
pro-apoptotic granule serine proteases (granzymes) in addition to the standard 
lysosomal proteins [124]. NK cells have pre-formed secretory lysosomes, whereas T 
cells need stimulation by the TCR to induce expression of the cytotoxic proteins [124, 
125]. Of importance to avoid self-damage, the low pH in the secretory lysosomes 
prevents the cytotoxic function of perforin [126]. Furthermore, perforin has a calcium-
dependent C2 domain at the C-terminus, mediating plasma membrane binding and 
cytotoxic activity. The higher calcium-level in the extracellular space is needed for the 
cytotoxic function [126]. The storage of secretory proteins in dense cores of the 
secretory lysosomes can protect them from degradation by other lysosomal proteins 
[124]. The secretory lysosomes also contain membrane-bound FasL, the ligand for the 
death receptor Fas. Polarized degranulation of the secretory lysosomes upon 
recognition of the target cells controls the delivery of the soluble cytotoxic proteins to 
the extracellular space between the effector cell and the target cell, as well as the 
delivery of FasL and TRAIL to the cell surface [124, 127].  
 
The protein lysosomal trafficking regulator (LYST) contains a BEACH (Beige and 
Chediak-Higashi)–domain, and is implicated in the function of secretory lysosomes. 
Different studies have indicated a role for LYST in the sorting and trafficking of 
proteins (Figure 2) [128]. Patients with bi-allelic mutations in LYST (CHS patients) 
have typical giant intracytoplasmic lysosomal structures in different cell types [74]. 
Clones of CTLs from CHS patients express normal levels of the soluble lytic proteins 
perforin and granzyme A and B, but show a defective capacity in the exocytosis of 
secretory lysosomes [129].  
 
The protein AP3 has a suggested role in the transport of proteins from the trans-Golgi 
network, to endosome- or lysosome-related organisms (Figure 2) [130]. CTLs from a 
patient with a homozygous mutation in the gene AP3B1, encoding one of the sub-units 
of AP3, have been described with a higher base-line level of LAMP1 (CD107a) [75, 
131], enlarged secretory lysosomes, and defective polarized secretion of the secretory 
lysosomes [131].  
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1.4.2 Target cell recognition 
Upon specific antigen binding of the TCR, naïve T cells requires several days for 
proliferation and acquisition of effector function, whereas NK cells are ready to kill 
with their pre-formed, perforin-containing secretory lysosomes. The antigen-specific 
TCRs is generated by somatic recombination during T cells development as described 
above.  
 
In contrast to CTLs, NK cells express a set of germ-line encoded receptors, which 
control activation, proliferation, and effector function [132]. As a consequence of the 
pre-formed cytotoxic granules, the cytotoxic function needs to be highly regulated in 
NK cells, with a fine-tuned balance between activating and inhibitory receptors [132, 
133]. Activation via receptors for natural cytotoxicity, by binding to ligands on the 
target cell, can directly initiate target cell killing. NKp46, NKp30, NKp44, NKG2D, 
2B4, and NKp80, are all activation receptors for natural cytotoxicity [133, 134]. 
NKp46, NKp30, NKp44, and 2B4 belong to the immunoglobulin superfamily whereas 
NKG2D and NKp80 belong to the C-type lectin receptor family [94]. In addition, NK 
cells express the low-affinity Fc-receptor IIIA (CD16) for recognition and killing of 
IgG coated target cells by ADCC [135]. The inhibitory receptors consists of two 
families; the killer cell Ig-like receptors (KIR) and the killer cell lectin-like receptors 
(KLR), which recognize MHC class I expressed by almost all cells and prevent killing 
of the normal cells [134]. An important mechanism is that lack of MHC I molecules on 
the target cells signals for killing, called the “missing self hypothesis” [136] .  
 
Target cell killing is controlled by engagement of different receptor signals for 
polarization and degranulation [137]. Binding of LFA-1 to its ligand intercellular 
adhesion molecule (ICAM)-1 induce polarization, but not degranulation, whereas 
engagement of CD16 by IgG induce degranulation but not polarization of the secretory 
granules in NK cells [137]. For target cell killing, engagement of both LFA1 and CD16 
is required [137]. Binding of 2B4 by its ligand CD48 result in weak polarization but no 
degranulation, whereas concurrent activation of 2B4 and CD16 result in polarization 
and killing, even without engagement of LFA1 [137]. 2B4 is a member of the signaling 
lymphocytic activating molecule (SLAM)-family and can either stimulate or inhibit NK 
cell activation via cytoplasmatic immunoreceptor tyrosin-based phosphorylated switch 
motifs. These motifs can recruit phosphatases for negative regulation or SLAM-
associated protein (SAP) for positive regulation. Binding of SAP leads to association 
with the Src kinase FynT, and protein tyrosine phosphorylation signals [138]. In SAP 
deficient cells, CD2 or CD16 induced NK cell cytotoxicity has been shown to be 
normal, whereas stimulation of 2B4 failed to induce cytotoxicity (Figure 2) [139].  
 
 
1.4.3 Immunological synapse 
Target cell recognitions activate down-stream signaling and trigger a number of events 
resulting in exocytosis of the secretory lysosomes. First, an immunological synapse is 
formed between the effector and the target cell through which the secretory granules 
can be exocytosed and delivered to the target cell (Figure 2).  
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In T cells, the TCRs are involved in forming the central supramolecular activation 
complex (cSMAC), which is surrounded by integrins (e.g., LFA-1) forming the 
peripheral SMAC (pSMAC) involved in the cell-cell adhesion [140-142]. However, the 
necessity of the formation of a stable synapse for cytotoxicity in CTLs has been 
questioned [143]. After activation, coordinated with the movement of the centromsome 
towards the synapse, actin accumulates at the synapse, and is reorganized to form a ring 
around the pSMAC, called the distal SMAC [141, 144]. Docking of the centrosome, 
microtubule organizing center, occurs next to the cSMAC, and directs the movement of 
the secretory granules towards the synapse [141]. The same mechanism has been 
observed in NK cells, resulting in delivery of the secretory lysosomes to a single focus 
spot at the immunological synapse [142].  
 
A recent study of the NK cell cytotoxic synapse has shown that the integrin LFA-1 
directs the organization and the transport at the immunological synapse. During 
degranulation, exocytosed LAMP-1 (CD107a) was accumulated in a central region of 
the synapse, where bi-directional vesicle traffic takes place [145].  
 
 
1.4.4 Exocytosis 
Exocytosis of the secretory lysosomes involves calcium-dependent signaling. Target 
cell recognition produces a signaling cascade which activates PLC$1, mediating 
generation of IP3 and diacylglycerol (DAG) from PIP2 [146]. The IP3 stimulates Ca2+ 
release into the cytoplasm from the endoplasmatic reticiulum, triggering extracellular 
Ca2+ influx through calcium release-activated calcium (CRAC) channels [146]. 
Activation of CRAC channels are dependent on STIM1 [146]. The store-operated Ca2+ 
entry of extracellular Ca2+ is crucial for exocytosis of the secretory granules and 
lymphocyte cytotoxicity [147]. DAG is accumulated at the immunological synapse 
[16], and drives the MTOC polarization towards the synapse in T cells [148, 149]. 
Engagement of LFA-1 in NK cells leads to TCR &-chain phosphorylation, SYK, and 
PLC-$ activation [150]. Other proteins involved in the LFA-1 induced polarization of 
secretory lysosomes are talin and the Wiscott-Aldrich protein [151]. 
 
The secretory lysosomes move along the microtubules towards the microtubule 
organizing center, in a minus-end directed transport mediated by the protein dynein. 
Myosin IIa has been demonstrated a function in the vesicle movement close to the 
synapse [152]. Kinesin-1, a mediator of plus-end-directed microtubule dependent 
transport, was recently described necessary for the terminal transport of the secretory 
lysosomes, in a complex with synaptotagmin-like protein 3 (Slp3) and Rab27a, 
suggesting a switch to ante-grade polarization before the final myosin IIa-dependent 
transport on actin and fusion with the plasma membrane [153]. Granules in Rab27a-
deficient cells have been shown to fail to dock at the synapse (Figure 2) [154, 155].  
 
Before the fusion with the plasma membrane occurs, the secretory lysosomes have to 
be primed. Munc13 proteins are involved in the priming step at synapses [156, 157]. 
Munc13-4 contains two C2 Ca2+-binding domains suggesting a Ca2+-dependent 
function. Exocytosis of the docked granules at the synapse is defective in Munc13-4 
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deficient cells, indicating a role of Munc13-4 in the priming of the vesicles before the 
fusion event in the immunological synapse (Figure 2) [67].  
 
Soluble N-ethylmaleimide-sensitive factor activating protein receptor (SNARE) 
proteins are implicated in the fusion event. A functional SNARE complex requires 
formation of a four-helix bundle between the fusing membranes. In the four-helix 
bundle, four distinct motifs must be represented; R-, Qa-, Qb-, and Qc-SNARE motifs 
[158]. The R-SNARE is usually vesicle associated, whereas Q-SNAREs are target-
SNAREs. Most of the SNARE proteins have one SNARE motif each, whereas SNAP-
proteins have two SNARE-motifs. The composition of the SNARE complex required 
for the fusion event in the immunological synapse is not fully elucidated. Vesicle-
associated membrane protein (VAMP)-7 and VAMP-8 have both been suggested as 
candidates for the R-SNARE motif, but knockdown experiments did not completely 
reduce the target cell killing [159, 160]. Patients with absent or defective syntaxin 11 
display defective exocytosis and target cell killing, that is partially restored by IL-2 
stimulation [161]. Munc18-2 in complex with syntaxin 11 is suggested to have a role in 
the fusion event by regulating docking and initiation of the SNARE complex (Figure 2) 
[69]. Munc18-2 deficient cells show defective degranulation and cytotoxicity [69].  
 
 
1.4.5 Target cell death 
Perforin is a pore-forming member of the membrane-attack-complex/perforin 
(MACPF) protein family [162, 163]. The structure of perforin share similarities with 
that of the complement factors in the membrane attack complex (MAC) [12]. Perforin 
is needed for the delivery of the pro-apoptotic granzymes into the target cell (Figure 2). 
However, the exact role of perforin is not clear. The C2 domain of perforin is required 
for Ca2+-dependent membrane interaction, and subsequent oligomerization into pores 
made of 18-20 molecules, with an internal diameter large enough for the delivery of 
granzymes [163]. One hypothesis is that the granzymes directly enter the target cell 
through perforin pores [163]. Another hypothesis involves an uptake of perforin 
together with granzymes in endocytic vesicles, and a perforin-mediated disruption of 
these vesicles in the cytosol [163].  
 
Granzyme B induces apoptosis in the target cell, whereas the role of other granzymes, 
including granzyme A, is less certain [164]. Granzyme A has been described to activate 
pro-inflammatory signals [165]. Apoptotic programmed cell death is fundamental for 
tissue homeostasis and occurs in a highly regulated series of events. In contrast to 
necrotic cell death, apoptosis typically does not induce inflammation. The series of 
events includes condensation of the nucleus and the cytoplasm, blebbing of the 
membrane, and generation of apoptotic bodies. The apoptotic bodies are rapidly 
recognized and ingested by phagocytic cells [166]. Apoptosis can be induced via 
different pathways; the intrinsic/mitochondrial pathway, the extrinsic/cell receptor 
pathway, or via granule exocytosis signals [166]. In the case of perforin-mediated 
lymphocyte cytotoxicity, granzyme B can directly induce apoptosis by cleavage of 
caspase 3, or indirectly via cleavage of Bid [167]. The truncated Bid translocates to the 
mitochondrial membrane and recruits Bax, which integrates with the mitochondrial 
membrane and induces release of cytochrome c from the mitochondria [168]. The 
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release of cytochrome c induces apoptosis via activation of caspase 9 and subsequently 
caspase 3 [169].  
 
X-linked inhibitor of apoptosis (XIAP) is broadly expressed in hematopoietic cells [80]. 
XIAP belongs to the family of inhibitor of apoptosis, and is an inhibitor of caspase 3, 7, 
and 9 [170], and also involved in signaling pathways [171]. Patients with XIAP-
deficiency suffer from XLP2, which is associated with development of HLH [80]. 
However, it is not clear how deficiency of XIAP causes disease. Cytotoxicity and 
degranulation is normal in XLP2 patients [80, 172].  
 
Target cell killing via the extrinsic pathway involves engagement of the death 
receptors. In CTLs and NK cells directed exocytosis of the secretory granules delivers 
FasL to the cell surface [127]. The induction of FasL requires Ca2+, but in contrast to 
the effector function of perforin, binding of FasL to its ligand is Ca2+-independent 
[173]. Engagement of the death receptors Fas and TRAIL initiate recruitment of the 
adaptor protein Fas-associated death domain (FADD), which in turn recruits caspase 8 
and 10. Active caspase 8 and 10 initiate the cascade that culminates in apoptotic cell 
death of the target cell [140].  
 
Studies on in vitro cleavage of the capspase-3-like substrate aspartate-glutamate-valine-
aspartate-7-amino-4-methyl-coumarin (DEVD-AMC) and proteolysis of the anti-
apoptotic protein Bcl-2 revealed that immune cells derived from FHL patients are not 
inherently resistant to apoptosis induction [174]. Specifically, etoposide-induced and 
Fas-triggered activation of intracellular caspases appear to remain intact in FHL 
patients. However, the degree of spontaneous activation of capsase-3-like enzymes in 
activated lymphocytes was decreased in most patients studied [174]. These studies 
were the first to suggest components of the perforin-granzyme system as the underlying 
defect in FHL [174].  
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Figure 2. Schematic view of perforin-mediated lymphocyte cytotoxicity, depicting 
steps where the proteins defective in different forms of primary HLH are involved.  
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2 AIMS OF THE THESIS 
 
The general aim of the thesis was to increase the clinical, genetic, and biological 
understanding of HLH and thereby improve diagnostics and survival for affected 
individuals. Furthermore, in a broader perspective, studies of the genetic and biological 
defects involved in lymphocyte cytotoxicity can gain insight into mechanisms of 
general significance for human biology.  
 
The specific aims were: 
 
Paper I:  
 
• to provide an updated estimate of the annual incidence of primary HLH in 
Sweden between 1987 and 2006. 
• to provide a minimal incidence of primary HLH, based on genetic and 
biological confirmed diagnoses, in Sweden between 2007-2011. 
• to describe the clinical presentation and outcome in the affected individuals. 
 
Paper II: 
 
• to determine the frequency of RAB27A mutations in a cohort of patients with 
primary HLH not harboring mutations in the FHL-causing genes PRF1, 
UNC13D, and STX11.  
• to describe the clinical presentation, including neurological involvement, in 
Griscelli syndrome type 2 patients. 
 
Paper III: 
 
• to describe how NK cell cytotoxicity and degranulation is affected by mutations 
in the genes encoding Munc13-4 and Rab27a. 
• to study how engagement of different receptors regulate exocytosis of secretory 
lysosomes.  
 
Paper IV: 
 
• to expand the spectrum of STXBP2 mutations in FHL5 patients. 
• to describe the clinical presentation of FHL5 patients. 
• to study NK cell function in FHL5 patients. 
 
Paper V: 
 
• to identify genetic defects in FHL patients without mutations in coding regions 
of PRF1, UNC13D, STX11, and STXBP2.   
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3 PATIENTS, MATERIAL, AND METHODS 
 
This section will in brief describe the patients and methods included in Paper I-V. For 
details of the protocols, readers are referred to the method section in the individual 
papers.  
 
3.1.1 Study populations and patient recruitment  
In the first part of Paper I, the study population consisted of all children below the age 
of 15 years during the period 1987-2006 in Sweden, in average 1 599 272 per year. For 
identification of patients with primary HLH, all pediatric centers in Sweden were asked 
to report their patients with a possible diagnosis of HLH between 1987-2006. In 
addition, the Causes of Deaths and the Swedish National Inpatient registries, both held 
by the National Board of Health and Welfare in Sweden, were used to identify patients 
with a relevant diagnosis according to the International Classification of Diseases 
(ICD) between 1987-1996 (ICD-9; 202D, 202X, 277W) and 1997-2006 (ICD-10; 
D76.1, D76.2, D76.3, C96.1), respectively. 
 
The patients included in the second part of Paper I and in Papers II-V have all been 
referred to us with a suspicion of HLH. The genetic studies started more than a decade 
ago, whereas functional studies of lymphocyte cytotoxicity have complemented and 
guided the genetic studies in the majority of patients since December 2005. After 
referral, sequence analyses of the known genes associated with FHL have been 
performed [175, 176, 177, unpublished data]. The patients were included in the 
different papers as specified below. In addition, healthy blood donors in Sweden have 
been used as controls. 
 
In the second part of Paper I, all patients with genetically verified primary HLH and/or 
defective NK cell function consistent with primary HLH referred to us 2007-2011 were 
included. 
 
In Paper II, 21 families, without identifiable mutations in the FHL-associated genes, 
PRF1, UNC13D, and STX11, were included. All patients fulfilled the HLH-2004 
criteria for HLH [63], and had either undergone HSCT or had a survival of less than 1 
year without HSCT. In the second part of Paper II, patients with a clinical diagnosis of 
GS2, from whom DNA was available, were included. In addition, we reviewed the 
medical literature of patients with RAB27A mutations.  
 
In Paper III, patients with bi-allelic mutations RAB27A (n=3) and UNC13D (n=4), 
from whom fresh blood cells were available for functional studies of cytotoxic 
lymphocyte function, were included. 
 
In Paper IV, patients without identifiable mutations in the FHL-associated genes, 
PRF1, UNC13D, and STX11 were included, whereof eight families were identified with 
bi-allelic mutations in STXBP2. 
 
  24 
In Paper V, Swedish infants with a known family history of HLH and/or defective NK 
cell cytotoxicity and/or degranulation between December 2005 and January 2011 were 
included. In addition, all patients from Sweden, Denmark, Norway, Finland, Slovenia, 
and Croatia with mutations in UNC13D identified at our unit were included in the 
study.  
 
 
3.1.2 Statistical analyses  
In Paper I, comparison between different categorical variables was performed by 
cross-tabulation using Pearson Chi-Square test, or alternatively the two-tailed Fisher’s 
exact test when expected frequencies were small. SPPS statistics (version 20, IBM 
Corp., Armonk, NY) was used for the analyses. In Paper III, co-localization of 
proteins, assessed by confocal microscopy, was quantified as the Pearson coefficient r. 
Student’s 2-tailed paired t-test was used for significance statistical analyses. Prism 
software (Version 5, Graph-Pad Software, La Jolla, CA) was used for analyses. In 
Paper V, statistical significance of results in the allele-specific quantitative real-time 
PCR was analyzed using the 2-tailed Mann-Whitney U test. SPPS statistics (version 20, 
IBM Corp.) was used for the analyses. 
 
 
3.1.3 Mutation detection 
Mutation detection by PCR and subsequent Sanger sequencing was performed in 
Paper I-V. First, genomic DNA was isolated from peripheral blood or, alternatively, 
from cultured fibroblasts according to standard procedures. Specific forward and 
reverse primers were designed for amplification of regions of interests by polymerase 
chain reactions (PCR), a method first described by Mullis et al. 1986 [178]. PCR 
facilitates selective, exponential amplification of DNA by denaturation of the double-
stranded DNA, annealing of the specific primers, and elongation by a polymerase. This 
occurs during repeated temperature changes, using a thermal cycler. Amplified 
fragments were subsequently directly sequenced using chain-terminating inhibitors, 
based on the method described by Sanger et al. 1977 [179]. Fluorescently labeled 
dideoxy analogues of the normal deoxynucleoside triphosphates are randomly 
incorporated in the DNA strands and function as inhibitors of the DNA polymerase, 
resulting in differently sized sequences. The synthesized fluorescently labeled DNA 
fragments were subsequently separated by size, by capillary electrophoresis on an ABI 
3730 Genetic Analyzer (Applied Biosystems, Foster City, CA). SeqScape software 
(Applied Biosystems) was used for sequence analysis. BigDye terminator Version 3.1 
Cycle Sequencing Kit (Applied Biosystems) was used for sequencing 
 
 
3.1.4 Assessment of NK cell cytotoxicity  
In Papers II-V, assessment of NK cell cytotoxicity was performed based on the 4 h 
51Cr-release assay described by Schneider et al. [180]. First, peripheral blood 
mononuclear cells (PBMCs) were isolated from peripheral blood by density gradient 
centrifugation. They were used as target cells, either freshly or activated by IL-2 
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(Proleukin, Novartis, Basel, Switzerland) incubation 36-60 hours. K562 cells (human 
erythroleukemia cell line, ATCC) were labeled with 51Cr and used as target cells. 
Effector and target cells were co-incubated for 4 hours at different effector-to-target 
cell ratios. Lysis of the target cells result in a 51Cr-release, which was measured using a 
gamma-counter. Lymphocyte cytotoxicity was calculated as lytic units (LU) at 25 % 
target cell lysis. A value of <10 LU was regarded as pathologically low. In Paper II, a 
value of 10-25 LU was defined as low. 
 
 
3.1.5 Assessment of NK cell degranulation  
Lamp-1, or CD107a, is a transmembrane protein in secretory lysosomes. Upon 
exocytosis of the secretory vesicles, the plasma membrane expression of CD107a is 
increased. This induction of CD107a expression was used to assess the exocytosis of 
secretory vesicles in Papers II-V [181]. Stimulation by K562 target cells was used for 
assessment of natural cytotoxicity, and stimulation by P815 (mouse mastocytoma cell 
line) cells coated with anti-CD16 was used to assess the ADCC. PBMCs were mixed 
with K562 cells or P815 cells supplemented with anti-CD16 antibody. Cells were 
incubated for 2 hours at 37°C in 5% CO2, then spun down and resuspended in PBS 
supplemented with 2% fetal bovine serum (FBS) and 2 mM ethylenediaminetetraacetic 
(EDTA). Cells were stained with anti-CD3, anti-CD8, and anti-CD56 (all BD 
Bioscience, Franklin Lakes, NJ), and analyzed by flow cytometric analysis 
(FACSCalibur, BD Biosciences). Data were analyzed using FlowJo software 
(ThreeStar, Ashland, OR). Lymphocytes were gated on forward/side scatter. NK cells 
were gated on CD3-CD56+ lymphocytes, and induction of CD107a surface expression 
('CD107a) was quantified.  
 
For intracellular labeling, cells were surface-stained, fixed with 4% formaldehyde 
(Sigma-Aldrich, St. Louis, MO) in PBS, permeabilized with PBS supplemented with 
2% FBS, 2 mM EDTA, and 0.5% saponin (Sigma-Aldrich), and stained with 
fluorochrome-conjugated anti-CD63, anti-CD107a, anti-granzyme A, and anti-perforin 
mAbs. 
 
 
3.1.6 Light and transmission electron microscopy of hair samples  
Irregular accumulation of pigment in hair shafts has been described in GS2 patients. To 
evaluate this in Paper II, light microscopy and electron microscopy of hair from GS2 
patients were performed. For light microscopy, small pieces of hair from the patients 
placed on a glass slide. The slides were mounted with Eukitt (O. Kindler GmbH & Co., 
Freiburg, Germany), and specimens were examined in an Eclipse C1000 microscope 
(Nikon, Tokyo, Japan). Images were obtained using a digital camera (DXM 1200F, 
Nikon) operating with ACT-1 software (Nikon). For transmission electron microscopy, 
small pieces of hair were fixed. Ultrathin sections of approximately 40–50 nm were cut 
and contrasted with uranyl acetate followed by lead citrate and examined in a Tecnai 10 
(Philips, FEI, Eindhoven, the Netherlands) at 80kV. Digital images were taken with a 
MegaView III digital camera (Soft Imaging System GmbH, Münster, Germany). 
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3.1.7 Immunofluorescence and confocal microscopy  
Confocal microscopy is an optical imaging technique, which compared to conventional 
microscopes allows for better optical resolution and reconstruction of three-
dimensional structures. In Paper III, confocal microscopy was used to study 
fluorescently labeled proteins involved in NK cell cytotoxicity upon engagement of 
different receptors. Purified NK cells were stimulated with phorbol 12-myristate 13-
acetate (PMA, Calbiochem, Darmstadt, Germany) and ionomycin (Sigma-Aldrich) and 
incubated together with S2 (Drosophila Schneider 2 cells) or K562 cells, or with 
ligand-coated beads on glass slides for 20 minutes at 37°C (Erie Scientific Company, 
Portdmouth, NH). In some experiments, cells were pre-treated with ML-9 
(Calbiochem) for 20 minutes. For coating of beads, protein A–coated beads (Bangs 
Laboratories, Fishers, IN) were washed twice in water, incubated with purified human 
IgG (Sigma-Aldrich), or recombinant human ICAM-1-Fc (a gift from E. Long, 
National Institutes of Health, Rockville, MD) for 2 hours at 4°C, then washed and 
resuspended in RPMI 1640 medium. After stimulation, cells were fixed with 4% 
paraformaldehyde in PBS, and subsequently permeabilized. For permeabilization PBS 
supplemented with 0.5% saponin was used. Reactions were blocked in PBS containing 
5% FBS, 0.1% BSA-c (Aurion, Wageningen, The Netherlands), and 2% normal 
donkey serum (Jackson ImmunoResearch Laboratories, West Grove, PA). Slides were 
mounted using Prolong Gold with 4,6-diamidino-2- phenylindole (Invitrogen, Paisley, 
UK), and images were acquired on a confocal microscope (DMIRE2, Leica, Solms, 
Germany) with a 63 ( glycerol objective, using Leica Confocal Software (Version 
2.61). ImageJ software was used for analyses (Version 1.410; Research Service Branch, 
National Institutes of Health, Bethesda, MD), with the Pearson correlation coefficient, 
r, determined using the JACOP plugin. Images for figures were generated by 
reconstruction of multiple optical sections. 
 
 
3.1.8 RNA extraction, cDNA synthesis and amplification, and analyses  
In Paper V, the UNC13D transcript was analyzed to identify a possible defect in 
splicing of the mRNA. Total RNA was extracted from white blood cells (RNeasy, 
QIAGEN, Hilden, Germany), and cDNA was synthesized with oligo(dT)20 primed 
reverse transcription (SuperScript III, Invitrogen) according to the manufacturer’s 
protocol. Overlapping cDNA fragments of UNC13D were amplified using 9 different 
specific primer pairs. For 3’-rapid amplification of cDNA ends (RACE) PCR, cDNA 
was synthesized using an oligo(dT)20 primer marked with an M13R-tag. This allowed 
sequencing of an unknown end of the transcript. Amplified products were separated by 
agarose gel electrophoresis, extracted (QIAquick gel extraction kit, QIAGEN), and 
cloned (TOPO-TA cloning kit, Invitrogen). Plasmid DNA was isolated (GeneJET 
plasmid miniprep kit, Fermentas, Glen Burnie, MD) and subsequently sequenced as 
described above. 
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3.1.9 Allele-specific quantitative RT-PCR  
For evaluation of a possible defect in the UNC13D transcript levels, allele-specific 
quantitative real-time PCR was performed in total white blood cells and in specific sub-
populations in Paper V. PBMCs were isolated by density gradient centrifugation, and 
specific cell populations were consecutively isolated by magnetic positive selection 
using anti–CD14, anti–CD4, anti–CD8, and anti–CD56 mAb-coated beads, 
respectively (Miltenyi Biotec, Bergisch Gladbach, Germany). Purity of the isolated cell 
populations was assessed by flow cytometry using fluorochrome-conjugated mAbs 
against CD3 (eBioscience, San Diego, CA), CD4 (Invitrogen), CD8 (Invitrogen), CD14 
(BD Bioscience), CD45 (BD Bioscience), and CD56 (BD Bioscience).  
 
RNA was isolated using TRIzol (Invitrogen) according to manufacture’s instructions, 
and cDNA was synthesized as described above. Two different reverse primers were 
designed for discrimination of a single nucleotide polymorphism, c.888G>C, located in 
exon 11 in UNC13D. 100 ng cDNA was mixed with 10 µL of Power SYBR Green 
PCR master mix (Applied Biosystems) and 10 pmol of forward and reverse primers in 
a total volume of 20 µL. The reactions were analyzed by real-time PCR (ABI 7900 HT, 
Applied Biosystems) using the standard curve method and analyzed with SDS software 
(Version 2.2.1, Applied Biosystems). 
 
 
3.1.10 Western blot analysis of Munc13-4 expression  
In Paper V, the genetic findings were confirmed with Western blot analyses. PBMCs 
were lysed in lysis buffer (20mM Tris, pH 7.4, 1mM EDTA, 1% Triton X-100, 150mM 
NaCl) with protease inhibitors (Roche Diagnostics, Basel, Switzerland), disrupted and 
centrifuged for 15 minutes at 14 000g. Protein content was determined by the Bradford 
assay (Bio-Rad, Hercules, CA). Protein was loaded and analyzed using SDS-PAGE 
separation and Western blotting (NuPAGE, Invitrogen). The rabbit polyclonal antibody 
to Munc13-4 (Protein Technologies Group, Chicago, IL), raised against amino acids 1-
236) and ERK1 (Santa Cruz Biotechnology, Santa Cruz, CA) were used for Western 
blotting. 
 
 
3.1.11 Genotyping of microsatellite markers 
For evaluation of haplotypes around the UNC13D locus, genotyping with microsatellite 
was performed in Paper V. Fluorescently labeled primers were used in PCR according 
to standard procedures. PCR products were separated by capillary electrophoresis on an 
ABI 3730 DNA Analyzer (Applied Biosystems) with GeneScan 400HD Rox (Applied 
Biosystems) as size standard and analyzed with Peak Scanner Version 1.0 software 
(Applied Biosystems). 
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4 RESULTS AND DISCUSSION 
 
4.1 EPIDEMIOLOGY 
The first incidence study of FHL was published in 1991 by Henter et al. [104]. In that 
study, an annual incidence of 1.2 per million children below the age of 15 years in 
Sweden, corresponding to around 1 per 50 000 live born children, was reported [104]. 
Sweden is a suitable country for incidence studies attributable to the well-organized 
personal identification numbers and a structured health care system with national 
registries. The population studied by Henter et al. consisted of all children below the 
age of 15 years in Sweden between the years 1971 and 1986. For identification of 
patients, all pediatric centers in Sweden were contacted and asked to report their 
patients with FHL and disorders resembling FHL. Furthermore, the causes of death 
according to death certificates of all children  (n=19 542 children) deceased during the 
study period were reviewed. Patients with previous immunosuppressive therapy, 
neoplastic cells, and Langerhans-cell histiocytosis were excluded from the study. In 
total, 32 patients were identified, of which 19 of 32 patients (66 %) were diagnosed 
with FHL post mortem.  
 
A Japanese incidence study reported the annual incidence of HLH to be 1.25 per 
million individuals in Japan [182]. Questionnaires were sent to 272 institutions with 
pediatric and adult hematologists in Japan, asking them to report patients with HLH, 
with a response rate of 74 %. In contrast to the study by Henter et al., the Japanese 
study included both patients with primary and secondary HLH. 3.5 % of the patients 
were classified as having FHL based on a familial history, a genetic diagnosis, an age 
<2 years, impaired NK cell function, or CNS involvement [182]. Altogether, 56.5 % of 
the patients reported were below the age of 15 years [182]. Infection-related HLH 
represented approximately half of the total number of cases, of which the majority was 
secondary to EBV-infections [182]. EBV-associated HLH is especially common in the 
Asian population [87]. Malignancy-associated HLH represented 23.3 % of the patients 
and 9.3 % were secondary to autoimmune diseases [182]. 
 
Since 1991, when the first incidence study in Sweden was published, the clinical and 
biological understanding of HLH has increased. Moreover, diagnostic guidelines are 
now available facilitating the diagnostics. We, therefore, in Paper I, hypothesized that 
the true incidence of primary HLH could be higher than previously estimated. Two 
different strategies were used for patient identification. First, written inquires were sent 
to all pediatric centers in Sweden, asking them to report their patients with HLH 
between 1987 and 2006. Secondly, data from the registries of the Swedish National 
Board of Health and Welfare were reviewed. Patients between 0 and 15 years of age 
were considered for inclusion, while those with an alternative diagnosis or with a 
malignant diagnosis at the time of diagnosis of HLH, suggesting secondary 
malignancy-associated HLH, were excluded from the study. Furthermore, patients with 
a relapse-free survival of more than one year off treatment were excluded from the 
study, regarded as most likely having secondary HLH. Medical files from 77 patients 
with possible HLH were requested from the treating medical centers. Of these 77 
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patients, 31 fulfilled at least five of the eight criteria for HLH according to HLH-2004 
(1987-1996: n=15, 1997-2006: n=16). In addition, six patients with missing values for 
at least three criteria but that fulfilled at least four of the criteria (1987-1996: n=6, 
1997-2006: n=0), and one patient with a known familial history (1987-1996: n=1, 
1997-2006: n=0), were still regarded as having primary HLH. 
 
Thus, in total 38 patients were regarded as having primary HLH in Sweden between 
1987 and 2006, giving an estimated annual incidence of 1.2 per million children aged 
less than 15 years, corresponding to 1.8 patients per 100 000 live born children. Hence, 
the estimated annual incidence was unchanged compared to what was reported by 
Henter et al. in 1991 [104]. Similarly, no major difference was seen in the annual 
incidence of primary HLH among the cohort of patients aged less than one year, eleven 
(1987-2006) compared to ten (1971-1986) per million children, respectively. Of note, 
the annual incidence in the northern part of Sweden (“Norrland”) was higher as 
compared to other parts of Sweden (“Svealand” and “Götaland”), 2.1 compared to 1.0 
and 1.1 per million children below the age of 15 years. A founder effect of an 
aberration causative of FHL, that will be discussed later on, in the northern part of 
Sweden (“Norrland”) together with a stronger inbreeding in this area [183], might 
contribute to the higher annual incidence. The second part of Paper I, aimed to provide 
a minimal incidence of primary HLH based on defective cytotoxic lymphocyte function 
and/or defective NK cell degranulation, or a verified genetic defect indicative of 
primary HLH. During the subsequent five-years period (2007-2011) twelve such 
patients were identified, giving an annual incidence of 1.5 per million children below 
the age of 15 years, corresponding to 2.2 patients per 100 000 live born children. 
 
Even though the awareness of HLH has increased and diagnostic guidelines are 
available, there are still difficulties in the diagnostics of HLH. The clinical presentation 
can vary markedly between different patients and some patients may still die before 
they are correctly diagnosed. In Paper I, patients with non-detected HLH are obviously 
not included in the study. In contrast, the study by Henter et al. included also patients 
identified through thorough review of all childhood deaths. This could contribute to an 
underestimation of the estimated incidence in Paper I. Moreover, in an attempt to 
exclude patients regarded as having secondary HLH, patients over the age of 15 years, 
patients with a disease free survival > 1 year without treatment, and patients with a 
malignant diagnosis at the time of HLH were excluded from the study. It is now known 
that patients with genetically verified primary HLH can present in adolescence or later 
[184, 185], Paper IV]. Furthermore, patients with hypomorphic mutations in the genes 
associated with primary HLH may present hematological malignancies [186]. This can 
also result in an underestimation of primary HLH in our study. 
 
SCID has previously been reported with an estimated minimal incidence of 1 per 100 
000 live births in France [187] and 1.4 per 100 000 live born children in a Swedish 
study [188]. Of note, a higher SCID incidence, 2.6 per 100 000 full-term neonates, was 
reported in a prospective population-based study using an assay enumerating the 
number of T cell receptor excision circle. A similar prospective screening of neonates, 
if feasible, would likely also reveal a higher true incidence of primary HLH.  
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4.2 GENETICS OF HLH  
4.2.1 Background 
When the projects included in this thesis were initiated 2007 three genes with FHL-
causing mutations were known; PRF1, UNC13D, and STX11 [66-68]. Their individual 
contribution to FHL varies in different populations [189, 190]. In a study by zur Stadt 
et al., 40 % of their FHL patients did not harbor mutations in PRF1, UNC13D, and 
STX11, ranging from 19 % in patients of Turkish origin to 70 % in patients of German 
origin [190]. In a study by Horne et al., 25 of 49 patients (51 %) of the families 
analyzed for mutations in PRF1, UNC13D, and STX11 were reported to be without a 
molecular diagnosis [189]. In patients from the Nordic countries, the proportion of 
patients without a molecular diagnosis was significantly higher (13 of 14 patients; 93 
%) compared to that observed in patients from Turkey (ten of 24 patients; 42 %) and 
the Middle East (two of eleven patients; 18 %) [189]. The high proportion of patients 
without a molecular diagnosis, especially in the Nordic countries, has been problematic 
in regards to diagnostics and carrier testing as well as for the possibility of prenatal 
diagnostics and preimplantation genetic diagnosis (PGD).  
 
 
4.2.2 RAB27A mutations 
As described in the introduction, GS2 is a primary immunodeficiency associated with 
development of HLH that is caused by mutations in RAB27A [72]. RAB27A encodes the 
221 amino acids protein Rab27a, a member of the small GTPase family involved in 
vesicular fusion and trafficking [72]. In addition to its role in cytotoxic lymphocytes, 
Rab27a, together with melanophilin and myosin Va, is required for the transport of the 
pigment-containing melanosomes [191]. Consequently, GS2 patients display a partial 
albinism in addition to the immunological defect [72]. In Paper II, we hypothesized 
that some of the patients diagnosed as having FHL instead could be affected by GS2, 
especially in the Nordic countries where many individuals normally are fair-haired. 
Accordingly, we identified heterozygous compound mutations in one Swedish family 
out of 21 families, which had been tested and found negative for mutations in PRF1, 
UNC13D, and STX11. This family included three affected individuals whereof two 
were identical twin-sisters, all previously diagnosed as having FHL. One of the 
identified mutations was novel, a substitution of the last nucleotide in exon 3, 
c.239G>C. This mutation is predicted to interfere with mRNA splicing by disrupting 
the consensus splice donor site [192]. The other mutation was a nonsense mutation, 
c.550C>T, introducing a premature stop codon, p.Arg184X, previously described by 
Menasche et al. [72]. None of the mutations were identified among 96 healthy blood 
donors.  
 
In the second part of Paper II, three patients with a clinical diagnosis of GS2 were 
analyzed for mutations in RAB27A. One patient of Danish origin, previously described 
by Trottestam et al. [113], harbored the above-mentioned p.Arg184X mutation in a 
homozygous state. The second patient, of Pakistani origin, was identified with a 
homozygous splice acceptor site mutation, c.240-2A>C, predicted to disrupt the mRNA 
splicing. This novel mutation was not identified among 96 healthy blood donors. The 
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third patient, of German origin, carried a homozygous mutation, c.148_149delinsC, 
previously described by Mamishi et al. [193], resulting in a frameshift and a premature 
stop codon, p.Arg50GlnFsX35.   
 
The identification of RAB27A mutations in three affected individuals from one family 
diagnosed with FHL highlights the importance of considering GS2 among patients with 
HLH, especially in fair-haired individuals as the partial albinism easily can be 
overlooked. Further strengthening this, two of the three patients included in part two of 
Paper II were first diagnosed as having FHL and only later correctly diagnosed as 
having GS2.   
 
 
4.2.3 STXBP2 mutations 
In 2009 two groups independently described STXBP2 as the fourth gene associated 
with FHL, more specifically with FHL5 [69, 70]. STXBP2 encodes the 593 amino acids 
protein Munc18-2. In the paper by zur Stadt et al. 13 patients of German, Turkish, 
Saudi Arabian, and Czech origin were described [70]. Together they harbored five 
different missense mutations, one 3 bp deletion, two frameshift deletions, and one 
splice acceptor site mutation of exon 15 [70]. The splice site mutation, c.1247-1G>C, 
frequently resulted in a deletion of exon 15 and a frameshift, introducing a stop codon, 
p.Val417LeuFsX126 [70]. In addition, other splice products were observed. 
Interestingly, all patients who developed HLH after the age of one year carried this 
specific splice site mutation on at least one of the alleles [70].  
 
In the paper by Côte et al., nine individuals of Saudi Arabian, Palestinian, and Turkish 
origin were described with mutations in STXBP2 [40]. Five patients from three 
families, all of Saudi Arabian origin, carried a homozygous missense mutation, 
p.Pro477Leu, whereas the remaining patients carried the above described splice site 
mutation, c.1247-1G>C [40]. The splice mutation was described to result in an in-frame 
exchange of the 17 first codons in exon 15 by 19 codons from the intronic sequence 
[40]. 
 
In Paper IV, we describe eleven patients from eight unrelated families diagnosed with 
FHL5. Nine of the patients carried bi-allelic mutations in STXBP2. In addition, two 
siblings, from whom DNA was not available for genetic analyses, were included. Four 
different missense mutations, one nonsense mutation, one out-of-frame deletion, two 
in-frame deletions, and one splice acceptor site mutation were identified among these 
patients. The splice site mutation, previously described by zur Stadt et al. [70] and Côte 
et al. [40], was identified in four of eight families of Caucasian or Asian origin. 
Altogether 43 % of the families reported by zur Stadt et al., Côte et al., and in Paper 
IV, carried this particular splice site mutation. In addition to the splice site mutation, 
one of the missense mutations, p.R405W had previously been described by zur Stadt et 
al. [70] while all the other mutations identified in Paper V were novel. None of the 
novel non-truncating mutations were identified among 95 healthy blood donors.  
 
In a subsequent paper by Cetica et al. four patients were described with four different 
missense mutations in STXBP2, whereof one was novel, p.Glu132Ala [194]. The so far 
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largest cohort of FHL5 patients was reported in 2012 by Pagel et al., where in total 37 
patients, from 28 families, with bi-allelic STXBP2 mutations were described [195]. 
Sixteen of the patients had previously been reported with STXBP2 mutation [70, 184].  
 
 
4.2.4 UNC13D mutations 
UNC13D was described as causative of FHL3 in 2003 [67]. Since then several papers 
describing the spectrum of mutations in UNC13D has been published [176, 189, 190, 
196-200]. A European collaborative effort to describe the genotype-phenotype in FHL3 
patients resulted in report of 84 FHL3 patients in 2011 [201].  
 
Altogether seven patients, from six unrelated families, in our patient cohort were 
identified with only mono-allelic mutations in UNC13D. This prompted us to search for 
mutations outside the coding regions of the gene in Paper V. A phylogenetic hidden 
Markov model based on sequences from 17 vertebrates was used for identification of 
evolutionary highly conserved regions [202].   
 
By this strategy, four highly conserved non-coding regions were identified. By 
sequence analysis, a variant, c.118-308C>T, was identified in one of the conserved 
intronic regions in five of the seven patients with mono-allelic UNC13D mutations but 
not in 96 healthy controls. This variant, in intron 1, had previously been described in a 
heterozygous state in one single patient diagnosed with FHL3 [196]. Two additional 
variants were identified in intron 1, constituting a common polymorphism 
c.117+59C>T (rs3744010) and a variant c.118–176G>C. The latter variant was 
identified in a homozygous state in three and in a heterozygous state in twelve of 96 
healthy blood donors, thus unlikely disease-causing. When sequencing other FHL 
patients without a known molecular diagnosis, two additional patients were identified 
with the same mutation, c.118-308C>T, in a heterozygous state, and, importantly, one 
patient was identified with this mutation in a homozygous state. Western blot analysis 
of whole cell lysates prepared from PMBCs from patients with the c.118-308C>T 
mutation did not show Munc13-4 protein.  
 
To elucidate whether the c.118-308C>T mutation had an impact on mRNA splicing, as 
previously suggested by Santoro et al. [196], or on the regulation of UNC13D 
transcription, the transcript was analyzed in patients and in heterozygous carriers of the 
mutation. Nine overlapping fragments of the UNC13D transcript were amplified in the 
patient homozygous for the c.118-308C>T mutation. Similarly as in the control, all 
fragments were readily amplified in the patient and subsequent sequencing revealed 
correctly spliced products indicating that the variant did not interfere with splicing. 
Next, allele-specific quantitative real time PCR was performed in heterozygous carriers 
of the c.118-308C>T mutation, which were also heterozygous for a linked 
heterozygous polymorphism in exon 11. Healthy individuals, carrying the 
polymorphism in a heterozygous state but not the c.118-308C>T mutation were used as 
controls. Analysis of transcription in white blood cells (WBCs) revealed a significantly 
diminished transcription of the allele with the polymorphism in heterozygous carrier of 
the intron 1 mutation representing only 27 % of the total transcripts compared to 50 % 
in the controls (p<0.05). For further evaluation of a possible role of the mutation in the 
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regulation of transcription, sequentially isolated CD14+, CD4+, CD8+, and CD56+ cells 
were used for allele-specific transcription as described above. Notably, the allele 
harboring the c.118-308C>T mutation represented less than 10 % of the transcript in 
CD4+, CD8+, and CD56+ cells. This was significantly less than what was observed in 
CD14+ cells. In the controls, the frequency of transcripts from the two different alleles 
was similar. These findings suggested an impact of the c.118-308C>T mutation 
specifically in lymphocytes. The sequence around the position of the intron 1 mutation 
displays homology to the Ets-1 and STAT4 consensus binding sites, which are 
disrupted by the mutation. This suggests that the sequence could represent an intronic 
enhancer of transcription. Of note, Ets-1 and STAT4 are both highly expressed in 
cytotoxic lymphocytes [203, 204]. Microsatellite analyses of carriers of the intron 1 
mutation indicated a common haplotype around the UNC13D locus, suggesting a 
founder effect. The intron 1 mutation has, in our laboratory, been identified in patients 
spread across Europe. 
 
The c.118-308C>T mutation was not identified in two of the original seven patients 
with mono-allelic UNC13D mutations. Importantly, two new patients were identified 
with monoallelic mutations harboring the c.118-308C>T in a heterozygous state. This 
suggested the presence of another non-coding aberration in UNC13D. Examination of 
SNPs located in exonic and intronic regions of UNC13D revealed a common haplotype 
on the second allele in patients with mono-allelic UNC13D mutations. Interestingly, 
other FHL patients, without a known molecular diagnosis, shared this second haplotype 
in a homozygous state. Nine overlapping fragments of the UNC13D transcript were 
amplified in three patients homozygous for this haplotype. In contrast to what was seen 
in healthy controls, the last two fragments were not amplified in the patients, 
suggesting an aberration affecting the 3’ end of the transcript. 3’-rapid amplification of 
cDNA ends PCR was performed to obtain the 3’ end sequence of the transcript. 
Cloning and sequencing of the PCR products revealed a correct sequence up to the end 
of exon 30, followed by a sequence blasted to a region 253 kb downstream of the gene 
using BLAT [205]. This suggested an inversion of 253 kb straddling the UNC13D 
locus. Sequence analysis mapped down the breakpoints to two 25 bp-fragments of Alu 
elements, identical in sequence. Similarly, genomic rearrangement by paring of 
inverted Alu repeats has been described in X-linked recessive hemophilia A and Alport 
syndrome [206, 207]. However, to the best of our knowledge this represents the first 
paracentric inversion alone responsible for an autosomal recessive disease in humans. 
A multiplex PCR assay was developed for easy detection of the inversion. One of 190 
healthy blood donors was found to carry the inversion in a heterozygous state. Western 
blot analysis of whole cell lysates prepared from PMBCs from patients with the 
inversion in a homozygous state did not show any Munc13-4 protein. Microsatellite 
markers indicated a common haplotype around the UNC13D locus in carriers of the 
253 kb inversion, all of Scandinavian origin. A geographic gradient was observed with 
a high frequency of the inversion in the northern part of Sweden, suggesting a founder 
effect.  
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4.2.5 Mutation spectrum of primary HLH  
Between December 2005 and January 2011, 13 Swedish patients with an age at onset 
below three years and that fulfilled the diagnostic criteria for HLH including defective 
NK cell cytotoxicity came to our attention (Figure 3). Of these, two patients carried bi-
allelic PRF1 mutations. One infant, of Afghani origin, harbored a novel PRF1 
mutation, p.Gly220Arg, whereas the other infant, of Swedish origin, harbored 
heterozygous compound mutations, p.Glu317Arg and p.Asp430Tyr, in PRF1. The 
latter patient has previously been described by Bryceson et al. [161]. One patient, of 
Somali origin, carried a novel homozygous mutation in UNC13D, p.Leu794ArgfsX2. 
These three patients are mentioned in Paper V. Importantly, the genetic aberrations 
identified in Paper II and Paper V could provide a molecular diagnosis for the 
remaining ten patients (77 %, Figure 3). Likewise, Côte et al. reported that the great 
majority of the FHL patients (90 %) in their cohort now have a known genetic 
diagnosis [69]. 
 
Figure 3. Mutated alleles in children aged less than three years that fulfilled the 
diagnostic criteria for HLH, including defective NK cell cytotoxicity in Sweden 
between December 2005 and January 2011.  
 
 
Patients provided a molecular diagnosis in studies included in this thesis are marked 
with a black arrow. Adapted from Paper V.  
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4.3 LYMPHOCYTE CYTOTOXIC FUNCTION IN PRIMARY HLH  
4.3.1 NK cell function in Griscelli syndrome type 2  
In Paper II, NK cell activity was evaluated in six patients carrying bi-allelic RAB27A 
mutations diagnosed as having GS2. One patient displayed an NK cell activity of 22 
LU, thus above the limit set as pathological. However, upon repeated analysis after 
treatment this had decreased to 1 LU. Similarly, two other patients had an NK cell 
activity above the limit set as pathological, 20 LU and 11 LU, respectively. NK cell 
activity in the remaining three patients was below 10 LU. Thus, only half of the 
patients initially had a defective NK cell function consistent with the diagnostic criteria 
for HLH [63]. 
 
In Paper III, analyses of NK cell function in GS2 patients as well as FHL3 patients 
with bi-allelic UNC13D mutations were performed. The three GS2 patients included in 
this paper were also included in Paper II. NK cell activity in all FHL3 patients was 
less than 10 LU. In 2007, Gazit et al. reported natural cytotoxicity but not CD16-
mediated ADCC to be defective in a patient with a homozygous RAB27A mutation 
[208]. To evaluate this in our cohort of patients, degranulation was assessed using the 
CD107a assay. In contrast to what was seen in healthy adult and infant controls, 
degranulation in the GS2 patients, as well as the FHL3 patients, was defective (< 3 %) 
after incubation with K562 cells. Similarly, anti-CD16 mAb stimulation induced 
degranulation in the controls, whereas degranulation was defective or impaired in the 
GS2 and FHL3 patients. Thus, our data suggest that degranulation induced by receptors 
for natural cytotoxicity or ADCC are Rab27a-dependent. The defects in cytotoxicity 
and degranulation were less profound in the GS2 patients compared to the complete 
loss of function in NK cell function seen in the FHL3 patients. This small residual 
cytotoxicity and degranulation is consistent with a later onset of HLH and longer 
periods of disease-free remission sometimes seen in GS2 patients [209]. Activation of 
the effector cells with IL-2 for 72 hours restored cytotoxicity and degranulation to a 
greater extent in GS2 patients compared to what was seen in the FHL3 patients.  
 
 
4.3.2 Function of Rab27a and Munc13-4 in exocytosis 
Munc13-4 has previously been shown to interact with GTP-bound Rab27a [210, 211]. 
However, the exact role of these proteins in the exocytosis of secretory granules is 
unclear. In Paper III, the localization of these proteins in relation to perforin in NK 
cells was assessed using confocal microscopy. In resting cells, Rab27a and Munc13-4 
did not display a general overlap with perforin. Upon activation of NK cells with PMA 
and ionomycin, perforin was clustered around a spot of #-tubulin labeling, at the center 
of microtubule network, likely reflecting the migration of the secretory lysosomes 
towards the microtubule organizing center. PMA and ionomycin stimulation 
significantly induced the colocalization of Rab27a with perforin, as well as the 
colocalization of Munc13-4 with perforin. Similarly, increased colocalization of 
Rab27a and Munc13-4 with perforin was observed after incubation with K562 in cells 
forming conjugates with the target cells. This corroborated findings previously reported 
in CTLs [212].  
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ML9, an inhibitor of myosin light chain kinase, was used to study whether the 
recruitment of Rab27a and Munc13-4 was myosin-dependent or not. The use of ML-9 
prohibited degranulation, and inhibited the colocalization of perforin with Rab27as and 
Munc13-4, respectively, in a dose-dependent manner. Thus the recruitment of Rab27a 
and Munc13-4 are myosin-dependent events. The activation-induced myosin-dependent 
colocalization of Rab27a and Munc13-4 with perforin suggests recruitment of these 
proteins from heterotypic vesicular compartments. In 2007 Menager et al. described a 
concept of lytic granule maturation requiring cooperation of endosome-derived 
exocytic vesicles and lysosome-related, perforin-containing vesicles in CTLs [212]. 
That study was performed using overexpression of fluorescently labeled membrane-
fusion proteins that together with chronic cytokine activation might alter cellular 
morphology and function. Thus, our findings that engagement of activation receptors 
induces endogenous Rab27a and Munc13-4 colocalization with perforin in freshly 
isolated NK cells provide support for some of their conclusions. 
 
Munc13-4 has previously been described as necessary for the recruitment of Rab27a in 
CTLs [212]. In Paper III, recruitment of Rab27a similarly failed in Munc13-4 
deficient NK cells. In our study of Rab27a-deficient cells, perforin was clustered at one 
point of the cells upon stimulation with PMA and ionomycin. However, Munc13-4 and 
perforin colocalization did not increase. These results suggest a reciprocal dependency 
of the presence of Rab27a and Munc13-4 for degranulation.  
 
As the next step, recruitment of Rab27a and Munc13-4 to the perforin-containing 
granules by engagement of individual receptors was investigated. As mentioned in the 
introduction, engagement of LFA-1 has been shown to induce polarization of the 
secretory lysosomes but not degranulation, whereas engagement of CD16 potently 
induces degranulation but not polarization [137]. In Paper III, engagement of LFA-1 
by ICAM-1-coated beeds was shown to significantly induce colocalization of Rab27a, 
but not Munc13-4, with perforin. Conversely, engagement of CD16 by IgG 
significantly induced colocalization of Munc13-4 but not Rab27a.  
 
In the next part of the study, Drosophila S2 cells, transfected with ICAM-1, CD48, or 
ULBP1, were used as target cells [213]. CD48 and ULBP1 are the ligands for the NK 
cell receptors 2B4 and NKG2D, respectively. For assessment of CD16-signalling, S2 
cells were incubated with human serum containing antibodies to oligosaccharide 
moieties expressed by the S2 cells [214]. The use of S2-ICAM-1 and serum-precoated 
S2 cells, respectively, corroborated the previous findings using the ICAM-1 and IgG-
coated beeds. NK cells conjugated to S2-CD48 or S2-ULBP1, alternatively, 
significantly induced colocalization of Rab27a, but not Munc13-4, with perforin. 
Conjugation with S2 cells coexpressing CD48 and ULBP1 induced colocalization of 
both Rab27a and Munc13-4 with perforin, and S2 cells coexpressing ICAM-1, CD48, 
and ULBP1 resulted in the greatest increase of colocalization. These data suggest that 
recruitment of Rab27a and Munc13-4 to perforin-containing granules is directed by 
qualitatively different signals from distinct receptors. For recruitment of Munc13-4, 
engagement of receptor(s) inducing high Ca2+ mobilization and degranulation was 
needed (CD16 or NKG2D and 2B4 synergy) in contrast to Rab27a that was recruited 
upon engagement of receptors not inducing strong Ca2+ influx or degranulation. 
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Ligands for the receptors that recruit Rab27a are in most physiological conditions more 
widely expressed than those needed for Munc13-4, indicating that signals for Rab27a 
recruitment might proceed those of Munc13-4 recruitment. 
 
 
4.3.3 NK cell function in FHL5 
In Paper IV, NK cell function was evaluated in nine of the eleven FHL5 patients 
described. NK cell function was pathologically low (<10 LU) in all patients tested. 
Furthermore, NK cell degranulation was assessed in eight of the patients. 
Degranulation in response to K562 cells was less than 2 % in all patients. Notably, after 
IL-2 stimulation for 48-72 hours, K562 cell lysis and degranulation increased 
considerably, similarly to what was seen in FHL4 patients harboring STX11 mutations 
[161]. These results are consistent with the findings reported by zur Stadt et al. and 
Côte et al. [69, 70]. 
 
 
4.3.4 NK cell function in different subgroups of FHL3 
FHL3 patients were first described with defective NK cell cytotoxicity and 
degranulation by Feldman et al. in 2003 [67]. Other papers have later confirmed the 
functional defects in FHL3 patients [176, 215] In Paper V, two novel genetic 
aberrations causative of FHL3 are described, a intron 1 mutation, c.118-308C>T, and a 
253 kb inversion straddling the UNC13D locus. NK cell function was evaluated and 
found defective in most patients with these aberrations. In patients harboring the intron 
1 mutation on at least one allele, NK cell-mediated lysis, determined as lytic units, was 
<10 LU (the limit typically regarded pathological) in all patients but one (11 LU). 
Similarly, of the FHL3 patients with at least one allele of the 253 kb inversion, all 
displayed pathologic NK cell cytotoxicity (<10 LU) except for one patient (13 LU). 
Importantly, all patients but two displayed normal or close to normal NK cell 
frequencies.  
 
Furthermore, degranulation in these groups of FHL3 patients, and in addition patients 
harboring other bi-allelic UNC13D mutation, was evaluated. Healthy controls and 
FHL2 patients were used as controls. In response to K562 cells, all patients with at least 
one allele carrying the intron 1 mutation displayed defective degranulation in opposite 
to the healthy adult and infant controls as well as the FHL2 patients. Among patients 
with at least one allele with the 253 kb inversion, three displayed degranulation ) 3 % 
(the limit set as pathological) during flares of HLH. Upon repeated analysis, 
degranulation was pathological in all patients. Of interest, degranulation by IL-2 
activated cells was significantly more increased in patients carrying the inversion on at 
least one allele as compared to patients with the intron 1 mutation and other UNC13D 
mutations. Likewise, cytotoxicity in IL-2 activated NK cells was higher in patients 
carrying allele(s) with the inversion relative to patients harboring the intron 1 mutation 
or other UNC13D mutations. Such increase of NK cell function in IL-2 activated cells 
have previously been observed in patients with missense mutations in UNC13D, as 
well as in FHL4 and FHL5 patients [69, 70, 161, 176, 184, 216].   
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4.3.5 Functional studies of primary HLH 
In summary, assessment of lymphocyte cytotoxicity has become important in the 
diagnostics of primary HLH and is of great value for guidance of genetic analyses, 
which often are time-consuming and expensive. As described above, pathological NK 
cell cytotoxicity is observed in patients with inherited defects in the perforin-mediated 
cytotoxic pathway. However, a decreased NK cell function can bee observed also in 
patients with reduced frequencies of circulating cytotoxic cells, as is often seen in 
patients with secondary HLH. Thus, assessment of NK cell cytotoxicity is not always 
sufficient for distinguishing between primary and secondary forms of HLH [217]. 
Therefore, other complementary methods are of value in the diagnostics of patients 
with suspected HLH. 
 
The use of degranulation assays in the diagnostics of primary HLH was recently 
evaluated in 494 patients with suspected HLH [217]. Quantification of NK cell 
degranulation using the 'CD107a assay with a 5 % cut-off provided a 96 % sensitivity 
and 88 % specificity for genetic degranulation disorders [217]. Active disease or 
immunosuppression did not affect results. In patients with secondary HLH, 98 % 
(n=59) displayed normal resting NK cell degranulation [217]. Assessment of NK cell 
degranulation was thus suggested useful in the differentiation between primary and 
secondary HLH [217]. 
 
FHL2 patients display a defective cytotoxic lymphocyte function whereas the 
degranulation is functioning [66, 161]. Expression of perforin assessed by flow 
cytometry is reduced in the great majority of FHL2 patients, and thus another important 
tool in the diagnosis of FHL2 patients [217]. FHL3, FHL4, and FHL5 patients all 
display both a defective cytotoxic function and defective degranulation [69, 70, 161]. In 
cells from FHL4 and FHL5 patients, a partial pick up of function after stimulation with 
IL-2 has been described [69, 70, 161]. Even though not typically seen in FHL3, a 
similar pick up of function in activated cells has been seen in some FHL3-patients such 
as the patients carrying the 253 kb inversion [176, 184, 217].  
 
Among other immunodeficiencies associated with development of HLH, cells from 
GS2 patients also display reduced NK cell cytotoxicity and degranulation [Paper II, 
Paper III, 186]. Similarly, NK cell function and degranulation have been described as 
deficient in patients with CHS [217, 218]. CTL cytotoxicity, assessed by a lysis assay 
on anti-CD3 labeled L1210 target cells, was absent in CHS patients with early onset 
HLH, whereas the CTL cytotoxicity was in the low normal range in patients who did 
not develop HLH [218]. Based on these data, CTL cytotoxicity was suggested 
predictive for the risk of development of HLH in CHS patients [187]. In CTLs from an 
HPS2 patient carrying bi-allelic AP3B1 mutations, cytotoxicity and degranulation was 
impaired [75, 131]. Of note, the base-line expression of CD107a in resting cells was 
reported higher than in the controls [75, 131].  
 
In XLP1 patients, 2B4-mediated NK cell cytotoxicity is defective, whereas CD2 and 
CD16 induced cytotoxicity is normal [139]. In contrast, XIAP-deficient cells from 
XLP2 patients do not show impaired NK cell mediated cytotoxicity [80, 172]. NK cell 
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degranulation after K562 stimulation is normal in most patients with XLP1 and XLP2 
[186]. Flow cytometric analysis of intracellular SAP and XIAP, respectively, is a rapid 
test proven helpful in the diagnosis of XLP1 and XLP2, respectively [219, 220].  
 
In summary, assessment of cytotoxic lymphocyte function and degranulation as well as 
flow cytometric analysis of intracellular perforin, SAP and XIAP are important tools in 
the diagnostics of primary HLH, and can guide the sequencing efforts. 
 
 
4.4 CLINICAL FEATURES AND LABORATORY FINDINGS IN PRIMARY 
HLH  
In this section clinical features and laboratory findings in the different groups of 
patients with primary HLH described in Papers I, II, IV, and V will be discussed. The 
findings are summarized in Table 3 (page 46). 
 
 
4.4.1 Age at diagnosis of HLH 
In Paper I, the median age at diagnosis of the 38 included patients with primary HLH 
was 5.1 months, ranging from 21 days to 14.7 years (mean = 28.5 months). In this 
study the underlying genetic defect was not studied, thus it was not possible to 
subgroup the patients genetically.  
 
In Paper II, the clinical presentations of six GS2 patients in our cohort and, in addition, 
all patients with confirmed RAB27A mutation reported in the English literature up to 
March 1, 2009 (n=37, 18 patients omitted due to a paucity of clinical data), are 
described. The median age at diagnosis, among the 18 patients with available data, was 
6.1 months, ranging from 1.8 months to 13.5 years (mean 31.5 months).  
 
Among the eleven FHL5 patients described in Paper IV, the median age at diagnosis 
was 19 months, ranging from 3.5 months to 17 years (mean = 58 months), whereas the 
median age at onset was 15 months, ranging from 2 months to 17 years (mean = 53 
months). Together with the FHL5 patients previously described by zur Stadt et al. [68], 
the median age at onset was 9 months ranging from 1.5 months to 17 years (mean = 30 
months, n=23).  
 
In Paper V, the median age at diagnosis among the eight FHL3 patients carrying the 
intron 1 mutation, c.118-308C>T, on at least one allele was 4.7 months, ranging from 
1.8 months to 7.5 months (mean = 4.5 months). The only patient with this mutation in a 
homozygous state was diagnosed with HLH at the age of 4.4 months. Among the 
twelve patients with the 253 kb inversion straddling the UNC13D locus in a 
homozygous state, the median age at diagnosis was 3.4 months, ranging from 1 day to 
15 months (mean = 5.2 months). The median age at diagnosis for FHL3 patients with 
bi-allelic disruptive UNC13D mutations has previously been reported to be 3 months 
[201]. Missense mutations in UNC13D have been associated with a later age at onset 
and milder defects in NK cell cytotoxicity and degranulation [176]. A partial 
restoration of NK cell cytotoxicity and degranulation, associated with a later onset of 
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HLH, are more commonly seen in FHL4 and FHL5 [69, 70, 161, 184]. However, in the 
patients carrying the inversion no difference was seen in the age at onset compared to 
other FHL3 patients, despite the partial restoration seen in NK cell cytotoxicity and 
degranulation.  
 
 
4.4.2 Family history and consanguinity 
In Paper I, 15 of the 38 patients (39 %) had familial disease, which was known at the 
time of diagnosis in ten of the patients. Three of the patients (8 %) were born to 
consanguineous parents. In Paper II, 21 of 35 GS2 patients (60 %) were reported with 
a familial disease, and 34 of 43 of the patients (79 %) were born to consanguineous 
parents. In Paper IV, six of ten FHL5 patients (60 %) had a familial disease and 
consanguinity was noted in three of ten patients (30 %). In Paper V, seven of 20 FHL3 
patients (35 %) had a familial disease, whereas none of the 19 patients with available 
information were born to consanguineous parents. 
 
 
4.4.3 Gender 
In Paper I, there was a small male predominance in the patient cohort (21 of 38 
patients, 55.3 %). A tendency of male predominance has previously been reported in 
other cohorts of primary HLH patients [111, 112]. This could hypothetically be 
addressed to an X-linked contribution in the underlying molecular defect. The 
underlying genetic defect was not studied, and XLP patients fulfilling the diagnostic 
criteria for HLH would be included in the study. This could result in a skewed gender 
ratio. However, also among the GS2 patients in Paper II, there was a male 
predominance, (24 of 43, 55.8 %). In contrast only 4 of 11 FHL5 patients (36 %) were 
of male origin in Paper IV. In Paper V, no skewed gender ratio was seen; ten of 21 
patients (47.6 %) were of male origin. Of note, Paper I is the only population-based 
study among those included in this thesis. 
 
 
4.4.4 Clinical presentation and laboratory findings in primary HLH 
In Paper I, the most common presentations of HLH were fever, splenomegaly, 
bicytopenia, and elevated sCD25 reported in 35 of 35 (100 %), 36 of 38 (95 %), 38 of 
38 (100 %), and eleven of eleven (100 %) of the patients with data available, 
respectively. Furthermore, 31 of 33 patients (94 %) had either elevated triglycerides 
and/or decreased fibrinogen, and 18 of 20 patients (90 %) had elevated ferritin. The 
only criterion that significantly changed in frequency over time was hemophagocytosis 
(p=0.047). Between 1987 and 1996, 20 of 21 patients (95 %) were reported with 
hemophagocytosis compared to eight of twelve patients (67 %) between 1997 and 
2006. This can possibly be attributable to the previous view amongst many treating 
physicians that hemophagocytosis was almost obligatory for the diagnosis, whereas it is 
now well-known that hemophagocytosis is not always evident, especially not in the 
early phase of HLH [55]. In addition, the suspicion of HLH was earlier possibly raised 
more often by findings of hemophagocytosis while the diagnosis now more often may 
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be investigated for at an earlier phase of the disease. In addition to the manifestations 
included in the eight criteria, the majority of the patients shared elevated liver 
transaminases and bilirubin as well as hyponatremia. 
 
Among the GS2 patients included in Paper II, fever, splenomegaly, and bicytopenia 
were also evident in the majority of patients, 36 of 38 (95 %), 30 of 35 (86 %), and 36 
of 38 (95 %), respectively. sCD25 was reported elevated in the only patient tested. 
Seventeen of 21 patients (81 %) had elevated triglycerides and/or decreased fibrinogen, 
and 14 of 17 patients (82 %) had elevated ferritin. Hemophagocytosis was found in 16 
of 24 patients (67 %).  
 
In Paper IV, all ten patients who developed HLH were reported with fever and 
splenomegaly and nine of ten (90 %) had bicytopenia. Furthermore, all ten patients that 
developed HLH were reported with elevated triglycerides and/or decreased fibrinogen. 
The two patients evaluated for sCD25 both had pathologically elevated levels. Eight of 
nine patients  (89 %) had elevated ferritin and six of ten patients (60 %) were reported 
with hemophagocytosis. In addition, nine of ten patients had elevated liver 
transaminases. In total, nine of the eleven FHL5 patients fulfilled the diagnostic criteria 
according to HLH-2004 [63]. One patient fulfilled 4 of 6 criteria evaluated and one 
patient was a healthy sibling with a confirmed genetic diagnosis. 
 
In Paper V, nineteen of the patients (90 %) were reported with fever, 20 of 21 (95 %) 
had splenomegaly, and 18 of 21 (86 %) had bicytopenia. Elevated triglycerides and/or 
decreased fibrinogen were seen in 19 of 21 (90 %) patients, 18 of 21 patients (86 %) 
had elevated ferritin and hemophagocytosis was noted in 10 of 20 patients (50 %). 
sCD25 was elevated in all ten patients evaluated. In all, 19 of 21 patients fulfilled the 
diagnostic criteria according to HLH-2004 [63], the remaining two patients both had a 
familial disease. 
 
 
4.4.5 Neurological manifestations 
In Paper I, 20 of 36 patients (56 %) of the patient displayed neurological alterations 
during the course of disease, whereas pathologic CSF was noted in 19 of 25 patients 
(76 %). Together, 26 of 36 patients (72 %) were reported with neurological alterations 
and/or pathological CSF. The most commonly reported neurological alteration was 
seizures. 
 
In Paper II, 21 of 38 (55 %) were reported with neurological alterations at diagnosis, 
and 29 of 43 patients (67 %) were reported with neurological alterations during the 
course of disease. Among the neurological alterations described, seizures and cranial 
nerve palsy were the most commonly reported. Pathologic CSF was noted in six of 
eleven patients (55 %). Data regarding CSF analyses were missing in the remaining 32 
patients. Interestingly, patients with reported onset/diagnosis at 12 months of age or 
above had a significantly higher frequency of neurological alterations compared to 
those with reported onset/diagnosis below 12 months of age (n=38, p=0.005). 
Furthermore, trends towards a lower proportion of the patients with a previously 
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affected relative were reported with neurological alterations (36 %) compared to those 
without (72 %, n=29, p=0.12).  
 
In Paper IV, neurological symptoms were observed in five of ten of the FHL5 patients 
(50 %) described. In two of these patients, irritability was the only neurological 
symptom. In addition one patient had a hearing deficiency of unknown origin, and one 
patient had an elevated CSF cell count but displayed no neurological symptoms.  
 
In Paper V, neurologic alterations were noted in eleven of 20 patients (55 %), and 15 
of 18 patients (83 %) had pathological CSF with pleocytosis and/or elevated protein 
levels during the course of disease. 
 
Taken together, many of the patients included in this thesis presented with neurological 
manifestations consistent with previous reports and knowledge of HLH. Of note, 
neurological manifestation may be the initial presentation of HLH and may dominate 
the course of disease [57, 221]. A high proportion of the GS2 patients in Paper II, 55 
%, displayed neurological alteration at diagnosis, compared to 37 % of the patients with 
HLH reported by Horne et al. [58]. However, the facts that one third of the GS2 
patients were without neurological alterations and that a previously affected relative 
may reduce the frequency of neurological alterations suggest that the neurological 
alterations are secondary to the inflammatory HLH state rather than a result of Rab27a-
deficiency in the CNS. Similarly, Pachlopnik Schmid et al. argued that the neurological 
symptoms in GS2 are secondary to the HLH in a single-center study describing 10 
patients with GS2 [222]. In contrast to this, the CNS disease in patients with CHS may 
progress after a successful HSCT, most likely due to a continuous lysosomal defect in 
neurons and glial cells [223]. 
 
A review of CNS involvement in primary HLH was recently published by Deiva et al., 
describing neurological manifestations at disease onset in 29 of 46 (63 %) patients with 
primary HLH who had undergone a neurologic evaluation and magnetic resonance 
imaging (MRI) within 2 weeks and 6 months of HLH diagnosis, respectively [224]. 
Twenty-three of the patients (50 %) had abnormal CSF at HLH onset [224]. The 
frequency of patients with genetically determined FHL with neurological symptoms at 
diagnosis was similar to what was seen in patients with other types of primary HLH 
[224]. As described above, Horne et al. have previously reported 72 of 194 (37 %) 
patients with neurological symptoms at diagnosis of HLH. In comparison with the 
study by Deiva et al., the cohort reported by Horne et al. had a higher mean age at 
onset and the patients were recruited from the multi-center study HLH-94. These facts 
may partly explain the discrepancy in the proportion of patients with neurological 
symptoms [58].  
 
In summary, neurological manifestations are common among patients with HLH. Many 
patients display neurological manifestations at onset of HLH, while other develops 
CNS disease during the course of disease. Thus, a correct diagnosis of HLH and 
prompt initiation of treatment is important in order to reduce the CNS disease and late 
effects often seen in patients with primary HLH. 
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4.4.6 Less common findings in primary HLH 
Among the six patients with GS2 in our cohort presented in Paper II, three were 
diagnosed with GS2 within our study. All three siblings were fair-haired but not 
considered abnormal by the treating physicians. Corroborating the genetic diagnosis, 
examination of hair shafts by light microscopy and electron microscopy revealed 
abnormal accumulation of pigment compared to what was seen in a healthy fair-haired 
child. Furthermore, two of the three additional patients were first diagnosed as having 
FHL and first later diagnosed with GS2. The partial albinism with silvery hair can 
easily be over-looked, especially in the Nordic population where fair hair is common. 
Hence, it is important to consider GS2 among patients with HLH.  
 
Interestingly, the data in Paper IV suggest that FHL5 can be associated with symptoms 
not typically seen in FHL patients. Gastrointestinal symptoms, 
hypogammaglobulinemia, and bleeding disorders were observed in approximately one 
third of the patients. The index patient in the study presented with an inflammatory 
bowel-like disease. Fecal calprotectin was elevated and colonoscopy revealed diffuse 
inflammation from cecum to the sigmoid colon, suggesting a possible diagnosis of 
inflammatory bowel disease. The colitis improved after treatment with oral mesalazin. 
This prompted us to review gastrointestinal symptoms in the other patients in the study. 
Two siblings both had chronic diarrhea, and other patients were observed with minor 
symptoms such as gastroesophageal reflux, vomiting, inflammation of lips and oral 
mucosa, and recurrent abdominal pain. Corroborating our findings, Pagel et al. in 2012 
reported that severe chronic diarrhea was observed in 14 of 37 FHL5 patients (38 %) 
[195]. The diarrhea was often present before the onset of HLH and persisted in at least 
six of eight patients who had undergone a HSCT [195]. Of interest, they observed a 
clear association between the gastrointestinal symptoms and patients not carrying the 
common splice site mutation, 1247-1G>C, suggesting that patients with that mutation 
have a remaining Munc18-2 function. The gastrointestinal symptoms observed in 
FHL5 patients could be attributed the impaired immunity and general 
hyperinflammatory state in HLH. Many other immunodeficiencies, including Wiscott-
Aldrich syndrome and SCID, are also associated with gastrointestinal symptoms [82, 
225]. Likewise, XLP2 patients commonly present with colitis [52]. An alternative 
explanation is that gastrointestinal symptoms are secondary to a loss of function of the 
Munc18-2 protein in cell types other than cytotoxic lymphocytes. The initial reports of 
Munc18-2 described a widespread expression in epithelial tissues, such as the intestines 
[226-228], and Munc18-2 could thus hypothetically act to maintain epithelial integrity.  
 
One patient in Paper IV displayed ecchymosis and a tendency of severe, prolonged 
bleeding. Furthermore, two siblings both had a prolonged coagulation profile, 
thrombocytopenia, and displayed petechiae. The notion of a possible bleeding disorder 
among FHL5 patients was also made by Pagel et al., reporting eight of 37 patients to 
have bleeding problems [195]. Several studies have reported a role of different Munc18 
isoforms in platelet function [229, 230]. Four FHL5 patients were identified with a 
secretion defect in platelets [231]. However, only one of those evolved a severe 
bleeding disorder [231]. Further studies might improve the understanding of a possible 
complicating bleeding disorder among FHL5 patients.  
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Hypogammaglobulinemia was noted among three of eleven patients (27 %) of the 
FHL5 patients in Paper IV, and among nine of 37 (24 %) in the report by Pagel et al. 
[195]. The hypogammaglobulinemia was typically seen after EBV-induced HLH 
episodes. Of note, hypogammaglobulinemia was also noted among FHL3 patients in 
the study by Pagel et al. [195]. Typically, hypogammaglobulinemia is seen in XLP1 
and XLP2, but seldom reported in FHL patients [80, 232, 233]. Some FHL5 patients 
have been demonstrated to have a loss in B-cell maturation, and a role of Munc18-2 in 
the B cell to T cell communication has been suggested [195]. However, it is still 
unclear how the loss of Munc18-2 contributes to the demise of humoral immunity in 
FHL5.   
 
One of the patients in Paper IV had a hearing deficiency of unknown origin. 
Interestingly, sensorineural hearing loss later was described in several FHL5 patients 
[195]. These patients was affected by a low-frequency hearing impairment, that easily 
can remain undetected [195]. It is unclear whether the deficiency is secondary to the 
inflammatory process or associated with a defective signal transduction mechanism of 
the inner ear [195]. Sensorineural hearing loss has previously been described in a 
perforin-deficient patient [234], but is usually not observed in FHL patients.   
 
 
4.4.7 Outcome 
In Paper I, altogether 14 of 38 patients (37 %) were alive at the time of evaluation. The 
great majority (34 of 38, 89 %) had been treated with a regimen including 
epipodophyllotoxin derivatives (etoposide, teniposide) during the course of disease. 
Between 1997 and 2006, all patients but one were treated according to the HLH-94 or 
HLH-2004 protocols [62, 63]. All patients alive have undergone a HSCT.  
 
Divided into two ten-years periods, a higher proportion of the patients survived until a 
HSCT in the second period, nine of 22 patients (41 %) 1987-1996 compared to 13 of 
16 patients (81 %) 1997-2006 (p=0.013, Pearson Chi-square test). Furthermore, an 
improved outcome after HSCT was seen the second period, even though not 
statistically significant, with 56 % mortality (five of nine patients) 1987-1996 compared 
to 23 % mortality (three of 13 patients) 1997-2006 (p=0.187, Fisher’s Exact Test 2-
sided). The overall survival was significantly higher the second period 1997 to 2006 
(ten of 16 patients, 63 %) compared to 1987 to 1996 (four of 22 patients, 18 %, 
p=0.005, Pearson Chi-square test). Among the patients diagnosed 1997-2006, the time 
period most comparable to HLH-94, the overall survival was slightly higher compared 
to the 5-year probability-of-survival reported in HLH-94 (54±6 %) [111]. The final 
report of HLH-2004 is not yet published. The improved survival the second 10-year 
period in Paper I could be attributable an increased awareness of primary HLH in 
Sweden, with improved diagnostics and treatment, including HSCT.  
 
Among all the GS2 patients reviewed in Paper II, 19 of 42 were alive (45 %). Of the 
six patients with GS2 in our cohort of patients all were alive at the time of evaluation. 
In Paper IV, nine of the eleven patients (82 %) described were alive. Two of the 
patients died before HSCT, whereas the third patient died of a reactivated adenovirus 
infection after a haploidentical HSCT. Of the eight patients alive, five have been 
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successfully transplanted. At the time of publication three patients were alive without 
HSCT. The possible prospective risk of hematological malignancy, high susceptibility 
of infections, and reactivation of HLH and neurological disease were discussed in the 
paper. Of importance, one of these non-transplanted patients developed an EBV-
positive classical Hodgkin lymphoma (cHL) 45 months after the clinical presentation of 
HLH (Machaczka et al. submitted). Of note, this patient did not present with HLH at 
the time of lymphoma development. The cumulative dose of etoposide given during 
HLH-therapy was low (0.2 g/m2). Similarly, Pagel et al. reported a patient, 
homozygous for the common splice site mutation in STXBP2, c.1247-1G>C, that 
developed cHL and HLH features at the age of 9 years [195]. These findings are of 
great importance in a clinical setting, suggesting that hypomorphic STXBP2 mutations 
might result in lymphoma development. This risk must be taken into account in the 
decision regarding HSCT in patients with defined disease-causing mutations in FHL 
genes. In Paper V, 16 of 21 FHL3 patients were treated according to the HLH-2004 
protocol, four were treated according to the HLH-94 protocol and one patient went 
directly to HSCT. Thirteen of 21 patients (62 %) are alive after a HSCT.  
 
It is difficult to compare the outcome in the different cohorts of patients with primary 
HLH reported in this thesis. The number of patients included in each cohort is limited 
and patients are treated at different centers in different time periods. The advances in 
the genetic and functional diagnostics of primary HLH will enable sub-categorization 
of patients with HLH and could possibly, together with other factors, be used in risk 
stratification for more individualized treatment in the future. 
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Table 3. Clinical data in the patients studied related to the period of diagnosis.  
 
 Paper I (%) Paper II (%) Paper IV (%) Paper V (%) 
Diagnosis Primary HLH GS2 FHL5 FHL3 
 
Total number of patients 38 43 (6+37*) 11 21 
Age at diagnosis     
     <3 months 13 of 38 (34) 3 of 18 (17)   1 of 10 (10)   8 of 21 (38) 
     3-11.9 months 10 of 38 (26) 8 of 18 (44)   4 of 10 (40) 10 of 21 (48) 
     1-2.9 years   5 of 38 (13) 1 of 18 (  6)   1 of 10 (10)   3 of 21 (14) 
     3-14.9 years 10 of 38 (26) 6 of 18 (33)   4 of 10 (40)  
Median age at diagnosis 5.1 m 6.1 m 19 m 4.7 m#/3.4 m§ 
Range age at diagnosis 21 d-14.7 y 1.8 m-13.5 y 3.5 m-17 y 1.8 m-7.5 m#/ 
1 d-15 m§ 
Familial disease  15 of 38 (39) 21 of 35 (60)   6 of 10 (60)   7 of 20 (35) 
Consanguinity   3 of 38 (  8) 34 of 43 (79)   3 of 10 (30)   0 of 19 (  0) 
Male gender 21 of 38 (55) 24 of 43 (56)   4 of 11 (36) 10 of 21 (48) 
Fever 35 of 35 (100) 36 of 38 (95) 10 of 10 (100) 19 of 21 (90) 
Splenomegaly 36 of 38 (95) 30 of 35 (86) 10 of 10 (100) 20 of 21 (95) 
Bicytopenia 38 of 38 (100) 36 of 38 (95)   9 of 10 (90) 18 of 21 (86) 
Triglycerides * / 
Fibrinogen + 
31 of 33 (94) 17 of 21 (81) 10 of 10 (100) 19 of 21 (90) 
Ferritin * 18 of 20 (90) 14 of 17 (82)   8 of   9 (89) 18 of 21 (90) 
Soluble CD25 * 11 of 11 (100)   1 of 1 (100)   2 of   2 (100) 10 of 10 (100) 
Hemophagocytosis 28 of 33 (67) 16 of 24 (67)   6 of 10 (60) 10 of 20 (50) 
Neurological alterations 
during the course of 
disease 
20 of 36 (56) 29 of 43 (67)   5 of 10 (50) 11 of 20 (55) 
Pathological CSF** 19 of 25 (76)   6 of 11 (55)  15 of 18 (83) 
Outcome -  proportion 
alive 
14 of 38 (37) 19 of 42 (45)   9 of 11 (82) 16 of 21 (62) 
* = patients with RAB27A mutations described in the English literature up to 1 March 2009, d=days, 
m=months y=years, # = patients with  ) 1 allele with the intron 1 mutation (c.118-308C>T),§Homozygous 
253-kb inversion straddling the UNC13D locus, ** CSF = cerebrospinal fluid, 
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
The papers included in thesis aimed to increase the clinical, genetic and 
biological understanding of HLH. The main conclusions are summarized 
below. 
 
• The annual incidence of primary HLH in Sweden 1987-2006 was estimated to 
be 1.2 per million children aged less than 15 years, corresponding to 1.8 per 100 
000 live born children.   
 
• The annual incidence was higher in the northern part of Sweden (“Norrland”) 
compared to the middle and southern part of Sweden (“Svealand” and 
“Götaland”), 2.1 compared to 1.0 per million children below the age of 15 
years.  
 
• A minimal annual incidence based on defective cytotoxic lymphocyte function 
and genetic defects indicative of primary HLH the subsequent 5-year period, 
2007-2011, was 1.5 per million children below the age of 15 years, 
corresponding to 2.2 per 100 000 live born.  
 
• One of 21 families diagnosed as having FHL was identified with bi-allelic 
mutations in the RAB27A gene consistent with the diagnosis of GS2. This 
highlights the importance of considering GS2 among patients with HLH, 
especially in fair-haired individuals where the partial albinism easily can be 
overlooked. 
 
• Neurological alterations were reported in a high proportion of patients with 
GS2, 55 % at diagnosis and 67 % during the course of disease. In comparison 
Horne et al. reported 37 % of patients with HLH to display neurological 
alterations at diagnosis.  
 
• Rab27a is required for degranulation induced by receptors both for natural 
cytotoxicity and ADCC. However, defects in cytotoxicity and degranulation 
were less profound in GS2 patients compared to FHL3 patients, consistent with 
late onset and long periods of remission sometimes seen in GS2 patients.  
 
• Activation of NK cells with PMA and ionomycin result in induced myosin-
dependent colocalization of Munc13-4 and Rab27a with perforin. A similar 
increase in colocalization occurs after incubation with K562 cells. 
 
• There is an inverse relationship between Rab27a and Munc13-4 where 
recruitment of Rab27a to perforin-containing granules is Munc13-4 dependent 
and vice versa.  
 
• Engagement of LFA-1, NKG2D, and 2B4 by their ligand ICAM-1, ULBP1, 
and CD48, respectively, induce colocalization of Rab27a but not Munc13-4 
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with perforin, whereas engagement of CD16 by IgG induces colocalization of 
Munc13-4 but not Rab27a with perforin. Thus, engagement of different 
receptors regulates distinct events for lytic granule maturation. 
 
• A highly variable disease severity was observed in our cohort of FHL5 patients, 
with an age at onset ranging from 2 months to 17 years. Furthermore, about a 
third of the patients presented with gastrointestinal symptoms, bleeding 
disorder, or hypogammaglobulinemia. Thus, the presentation of FHL5 can be 
diverse and the diagnosis should also be considered in patients with 
manifestations other than those typically associated with HLH. 
 
• NK cell cytotoxicity and degranulation were defective in all FHL5 patients 
evaluated. Notably, IL-2 stimulation partially restored the defect, as previously 
seen in FHL4 patients. 
 
• The identification of mutations in HLH-associated genes in late-onset patients 
with an atypical presentation raises questions regarding treatment. A possibly 
increased risk of hematological malignancies over time, and the risk that an 
HLH relapse sometimes may be complicated with neurological alterations, must 
be taken under consideration if HSCT is postponed. 
 
• The point mutation, c.118-308C>T, located in the intron 1 of UNC13D, 
selectively impairs UNC13D transcription in lymphocytes and was identified in 
patients spread over Europe.  
 
• A 253 kb inversion straddling the UNC13D locus was identified in patients of 
Scandinavian origin. The mutation affects the 3’end of the transcript and 
abolishes Munc13-4 expression. 
 
• The identification of two non-coding aberrations causative of FHL3 provides a 
molecular diagnosis for many patients of northern European origin and 
highlights aberrations outside the coding regions as a cause of disease. Our 
findings make a case for sequencing of evolutionary conserved regions in the 
diagnostics of primary immunodeficiency syndromes. 
 
Together, the findings in this thesis have provided a molecular diagnosis for the great 
majority of children with a typical form of primary HLH in Sweden, as well as many 
patients in other parts of Scandinavia and other countries. Identification of the 
underlying genetic defect is of great value in the diagnostics of HLH, which often can 
be challenging. An early diagnosis is important for prompt initiation of adequate 
treatment and thus also for an improved outcome and reduced late effects, including 
neurological alterations. Moreover, Guthrie-card based neonatal screening for the 
common 253 kb inversion is currently being discussed in Sweden in order to identify 
patients with FHL3 before onset of HLH. In addition, a genetic diagnosis provides the 
possibility of carrier testing, prenatal diagnosis, and preimplantation genetic diagnosis 
for the affected families.  
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The findings in this thesis also include epidemiological data about the incidence of 
primary HLH in Sweden, and describe the clinical presentation and laboratory findings, 
including NK cell function, in different subcategories of patients with HLH.  
 
Lymphocyte cytotoxic function can, simplified, be viewed as a continuous range, 
where patients with truncating mutations in HLH-associated genes constitute one end 
of the spectrum, with a complete absent function. Hypomorphic mutations, such as 
missense mutations and splice site mutations in genes associated with primary HLH, 
are examples where a reduced, but not fully absent, lymphocyte cytotoxic function is 
observed. These mutations have been associated with later age at onset and a more 
atypical presentation of disease. Based on the fact that the clinical presentation of 
primary HLH can vary considerably, and include symptoms not typically associated 
with HLH, an increased awareness of HLH is needed not only among clinicians within 
the field of pediatric hematology but also for adult hematologists, infectious disease 
specialists, gastroenterologists, and intensivists. Furthermore, the knowledge of the 
diverse presentation of primary HLH stresses the difficulties in the discrimination 
between primary and secondary HLH, which is of importance in regards to treatment 
and the decision of HSCT.  
 
To further increase the understanding of HLH, and other immunodeficiencies, 
continued translational research is needed, with a close collaboration between clinicians 
and researchers. With more fine-tuned assessment of functional defects in the immune 
system, together with the sequencing advances in the field of genetics, many novel 
primary immunodeficiencies will likely be revealed in the near future. Whole exome 
sequencing is now frequently used and whole genome sequencing will add on further 
with the possibility to detect non-coding variants, shown in this thesis to be important at 
least in the case of primary HLH. The great challenge will be to interpret all data in this 
complex field of human immunity. Hopefully, improved diagnostics and sub-
categorizing of patients can catalyse a more individualized treatment in HLH and other 
immunodeficiencies.  
 
The work with this thesis has been very rewarding and has for me been a great example 
of translational research and collaboration between different fields of science. It has 
also provided close contact with many treating clinicians and sometimes also with the 
affected families. My sincere hope is to be involved both in the research and in a 
clinical setting of this interesting field in the future. 
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6 SVENSK SAMMANFATTNING 
 
Denna avhandling omfattar studier av hemofagocyterande lymfohistiocytos (HLH). 
Målsättningen har varit att öka den kliniska, genetiska och biologiska kunskapen av HLH för att 
på så sätt förbättra diagnostik och överlevnad för drabbade individer.  
 
HLH innebär ett livshotande, hyperinflammatoriskt tillstånd med symptom såsom feber, låga 
blodvärden samt lever- och mjältförstoring. HLH kan även drabba det centrala nervsystemet och 
ge svåra neurologiska symptom med kramper och förlamning. HLH delas vanligtvis in i två olika 
grupper, medfödd/primär HLH och förvärvad/sekundär HLH. I gruppen primär HLH ingår 
familjär hemofagocyterande lymfohistiocytos (FHL) som nedärvs autosomalt recessivt. Detta 
innebär att föräldrar som är bärare av ett sjukdomsorsakande anlag har 25 % risk att få ett sjukt 
barn. FHL är dödlig utan adekvat terapi. Behandlingen innefattar vanligen två steg. Först dämpas 
den intensiva hyperinflammationen med cellgifter och kortison. I ett andra steg görs en 
hematopoietisk stamcellstransplantation, vilket är nödvändigt för bot av den ärftliga formen av 
HLH. Med nuvarande behandling överlever drygt 50 % av individer drabbade av HLH. Hittills 
finns fyra gener kopplade till FHL (PRF1, UNC13D, STX11, och STXBP2). Defekter i dessa 
gener leder till avsaknad av, eller nedsatt, cytotoxicitet (cellers förmåga att döda målceller). 
Cytotoxiciteten är viktig i försvaret mot virusinfektioner och tumörceller samt även i 
nedregleringen av det egna immunförsvaret. Sjukdomsbilden vid HLH kan variera och det är 
därför ibland svårt att komma fram till rätt diagnos. Vidare kan det klinisk vara omöjligt att 
särskilja primär HLH och sekundär HLH. Ökad genetisk och biologisk förståelse av HLH är 
därför av största vikt för en korrekt diagnos och för planering av behandling.  
 
År 1991 beskrev vår grupp att primär HLH drabbade 1.2 av 1 000 000 barn under 15 år. Sedan 
dess har kunskapen om FHL ökat och vi hypotiserade därför att den sanna incidensen kunde vara 
högre en tidigare estimerat. I den första delen av delarbete I visar vi dock, något överraskande, att 
den årliga incidensen av sjukdomen är oförändrad, 1.2 per 1 000 000 barn under 15 år vilket 
motsvarar 1.8 barn per 100 000 levande födda. I Sverige innebär det att ungefär 2 barn per år 
drabbas av primär HLH. I den andra delen av delarbete I beskriver vi genetiska analyser och 
studier av Natural Killer (NK) cellers cytotoxicitet som diagnostiska hjälpmedel för att hitta 
patienter med primär HLH. 
 
Många individer med primär HLH har varit utan en genetisk diagnos, detta gäller särskilt 
individer av nordiskt ursprung. En av de viktigaste målsättningarna med denna avhandling var 
därför att hitta den underliggande genetiska orsaken till HLH hos dessa individer. Patienter med 
Griscelli syndrom typ 2 (GS2) drabbas också av HLH men uppvisar i tillägg till immunbristen en 
partiell albinism. I delarbete II visar vi att en av 21 familjer som fått diagnosen FHL istället var 
drabbade av GS2 med mutationer i genen RAB27A. Ytterligare tre patienter var initialt 
diagnosticerade med FHL och fick först senare den korrekta diagnosen GS2. Detta visar att det är 
viktigt att komma ihåg GS2 hos patienter med primär HLH eftersom den partiella albinismen kan 
vara svår att upptäcka. I delarbete II presenterar vi även en sammanställning av alla GS2 
patienter med mutationer i RAB27A som har rapporterats i den medicinska litteraturen.  
 
Delarbete III innehåller studier av funktionen av Rab27a (proteinet som kodas av genen 
RAB27A) och Munc13-4 (proteinet som kodas av genen UNC13D) i NK celler. Båda dessa 
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proteiner behövs för en normal NK-cellsfunktion. Vi visar även hur aktivering av specifika 
receptorer på NK-celler yta påverkar vad som händer med dessa proteiner i cellen och hur Rab27a 
och Munc13-4 är beroende av varandra för en korrekt funktion.  
 
I delarbete IV beskriver vi sjukdomsbild, mutationsspektrum och NK-cellsfunktion hos patienter 
med FHL som orsakas av mutationer i genen STXBP2. Sjukdomsbilden är väldigt varierade och 
debutålder sträcker sig från 2 månader till 17 år. Många av patienterna uppvisade symptom som 
inte vanligtvis ses vid HLH, såsom besvär från mag-tarmkanalen, blödningsbenägenhet och låga 
nivåer av antikroppar i blodet. Det är därför viktigt att komma ihåg FHL som diagnos även hos 
patienter med en annorlunda, atypisk, sjukdomsbild. 
 
I delarbete V beskriver vi två olika förändringar utanför de kodande delarna av genen UNC13D 
som en vanlig orsak till FHL i Sverige och övriga Europa. Vid konventionell genetisk analys 
undersöks enbart de kodande delarna och dessa förändringar har därför tidigare inte upptäckts. 
Dessa två förändringar, en punktmutation i intron 1 och en inversion med ena brottspunkten i 
intron 30, gör att inget Munc13-4-protein bildas och orsakar således en defekt NK-cellsfuktion.  
 
Sammanfattningsvis så har fynden i denna avhandling gjort att den absoluta majoriteten av barn 
med en typisk form av primär HLH i Sverige, samt även många patienter utanför Sverige, kan få 
en genetisk diagnos som förklarar sjukdomen. Vidare har resultaten i denna avhandling gett ny 
kunskap om hur vanligt primär HLH är i Sverige samt om sjukdomspanorama och NK-
cellsfunktion i olika grupper av patienter med primär HLH. En genetisk diagnos, tillsammans med 
analys av NK-cellers funktion, underlättar handläggningen av patienter med HLH och är således 
av största vikt för insättande av livräddande behandling. Tidig diagnos och behandling kan också 
minska risken för kvarstående neurologiska symptom hos drabbade individer. En genetisk diagnos 
möjliggör också fosterdiagnostik och anlagstestning av syskon och släktingar vilket kan vara till 
stor nytta för drabbade familjer.  
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